var title_f33_8_33920="Revascular silent ischemia";
var content_f33_8_33920=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74612%7ECARD%2F65904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74612%7ECARD%2F65904&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Revascularization improves outcome in silent ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 348px; height: 458px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Top panel: Among 558 patients with silent ischemia who were randomly assigned to angina guided drug therapy, drug therapy guided by silent ischemia, or revascularization, mortality was significantly reduced mortality with revascularization compared to the other two options. There was no difference between angina and ischemic guided strategies. Bottom panel: The two year rate of death or myocardial infarction (MI) was significantly lower only when revascularization was compared to angina guided therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Davies RF, Goldberg D, Forman S, et al. For the ACIP Investigators, Circulation 1997; 95:2037.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 492px\">",
"   <div class=\"ttl\">",
"    Revascularization improves outcome in silent ischemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 472px; height: 318px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The ACIP study randomized 558 patients with silent ischemia to angina-guided drug therapy, drug therapy guided by elimination of angina and silent ischemia, or revascularization with angioplasty or surgery. After a two year follow-up, the cumulative rate of death, myocardial infarction, or cardiac hospitalization was significantly lower in patient undergoing revascularization compared to those with ischemia or angina-guided drug therapy (23 versus 39 and 42 percent, respectively, p&lt;0.003). There was no difference in outcome between the angina or ischemia-guided groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Davies RF, Goldberg D, Forman S, et al. For the ACIP Investigators. Circulation 1997; 95:2037.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33920=[""].join("\n");
var outline_f33_8_33920=null;
var title_f33_8_33921="Mouth frown";
var content_f33_8_33921=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F76339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F76339&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Mouth frown",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 347px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A downward turn of the corners of the mouth at rest (mouth frown) can occur as a normal feature of aging.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33921=[""].join("\n");
var outline_f33_8_33921=null;
var title_f33_8_33922="Symptoms and diagnosis of attention deficit hyperactivity disorder in children";
var content_f33_8_33922=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Symptoms and diagnosis of attention deficit hyperactivity disorder in children (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/8/33922/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33922/contributors\" id=\"au4805\">",
"       Kevin R Krull, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/8/33922/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33922/contributors\" id=\"se219\">",
"       Marilyn Augustyn, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?33/8/33922/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33922/contributors\" id=\"de5754\">",
"       Mary M Torchia, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/8/33922?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ATTENTION DEFICIT HYPERACTIVITY DISORDER OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Attention deficit hyperactivity disorder (ADHD) is a medical condition with symptoms of inattention, hyperactivity, and impulsivity. It is often first recognized in early childhood. The symptoms affect a child's cognitive, academic, behavioral, emotional, and social functioning, and the condition often continues into adulthood.",
"    </p>",
"    <p>",
"     Approximately 8 to 10 percent of children aged 4 to 17 years have ADHD, making it one of the most common disorders of childhood. It occurs two to four times more commonly among boys.",
"    </p>",
"    <p>",
"     The symptoms and diagnosis of ADHD will be reviewed here. The treatment of ADHD is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/53/35668?source=see_link\">",
"      \"Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      ADHD CAUSES",
"     </span>",
"    </p>",
"    <p>",
"     The cause(s) of ADHD are not clear, although there are a number of theories. Most experts agree that ADHD is a medical or neurodevelopmental disorder. Many experts believe there is an inherited imbalance of chemicals in the brain. This is supported by the improvements often seen with the use of medications that affect these chemicals.",
"    </p>",
"    <p>",
"     Exposure to tobacco before birth may increase the risk of developing ADHD. Most experts do not feel that dietary factors (food additives, sugar, food sensitivity, mineral deficiency) cause ADHD. It is possible that some children have mild behavioral changes in response to certain foods or food additives. However, these changes do not meet the diagnostic criteria for ADHD. (See",
"     <a class=\"local\" href=\"#H9\">",
"      'Diagnostic criteria'",
"     </a>",
"     below.)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      ADHD SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     ADHD is a condition that can cause three categories of symptoms: hyperactivity, impulsivity, and inattention. Children with ADHD may have one or more of these symptoms and the symptoms may change in frequency or pattern as the child develops. In most situations, the child has difficulty controlling his or her behavior or attention and may have difficulty anticipating the consequences of his or her behavior. The child does not usually misbehave because he or she is willful or wants to annoy those around him or her.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Hyperactivity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Hyperactive behavior is defined as excessive fidgetiness or talking, difficulty remaining seated when required to do so, difficulty playing quietly, and frequent restlessness or always seeming to be \"on the go.\"",
"    </p>",
"    <p>",
"     These symptoms are usually seen by the time a child is 4 years old and typically increase over the next three to four years. The symptoms may peak in severity when the child is 7 to 8 years of age, after which they often begin to decline. By the adolescent years, the hyperactive symptoms may be less noticeable, although ADHD can continue to be present.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Impulsivity",
"     </span>",
"     &nbsp;&mdash;&nbsp;Impulsive behavior almost always occurs with hyperactivity in younger children. It can cause difficulty waiting turns, blurting out answers too quickly, disruptive classroom behavior, intruding or interrupting others' activities, rejection by classmates, and unintentional injury.",
"    </p>",
"    <p>",
"     Similar to the hyperactive symptoms, impulsive symptoms are typically seen by the time a child is 4 years old and increase during the next three to four years to peak in severity when the child is 7 to 8 years of age. However, impulsive symptoms usually continue to be a problem throughout the life of the individual.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Inattention",
"     </span>",
"     &nbsp;&mdash;&nbsp;Inattention may take many forms, including forgetfulness, being easily distracted, losing or misplacing things, disorganization, underachievement in school, poor follow-through with assignments or tasks, poor concentration, and poor attention to detail.",
"    </p>",
"    <p>",
"     Because of the developmental demands on a child (eg, needing to pay attention, sit still), these problems may become more obvious in school when the child is 8 to 9 years old, although the child may have symptoms at a younger age when at home. Inattention is most likely to persist through adolescence and potentially into adulthood.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Types of ADHD",
"     </span>",
"     &nbsp;&mdash;&nbsp;Three subtypes of ADHD have been identified:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The predominantly inattentive type, previously known as attention deficit disorder",
"      </li>",
"      <li>",
"       The predominantly hyperactive-impulsive type",
"      </li>",
"      <li>",
"       The combined type",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     The subtype is determined based upon a child's predominant symptoms, and can change over time.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H8\">",
"     <span class=\"h1\">",
"      ADHD EVALUATION AND DIAGNOSIS",
"     </span>",
"    </p>",
"    <p>",
"     Parents who are concerned their child may have ADHD should speak with the child's healthcare provider. Early recognition and treatment of ADHD are important to prevent or limit emotional, academic, and behavioral difficulties.",
"    </p>",
"    <p>",
"     There is no simple test to diagnose ADHD. In addition, many of the symptoms of ADHD are common among 4- to 6-year-old children, but tend to occur with less frequency",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     intensity than in children with ADHD. Thus, it may be difficult for parents to tell if their young child has ADHD or is simply behaving as young children often do. However, studies that evaluate children over time have confirmed that most preschool children who meet all the criteria for ADHD will continue to do so as they get older.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Diagnostic criteria",
"     </span>",
"     &nbsp;&mdash;&nbsp;Criteria for the diagnosis of ADHD have been defined by the American Psychiatric Association. There are several important features of these criteria, including the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The symptoms must be present in more than one setting (eg, school and home).",
"      </li>",
"      <li>",
"       The symptoms must persist for at least six months.",
"      </li>",
"      <li>",
"       The symptoms must be present before the age of 7 years.",
"      </li>",
"      <li>",
"       The symptoms must impair function in academic, social, or occupational activities.",
"      </li>",
"      <li>",
"       The symptoms must be excessive for the age of the child.",
"      </li>",
"      <li>",
"       Other mental disorders that could account for the symptoms must be excluded.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     There are a number of other medical and psychological conditions that have symptoms similar to those of ADHD. A thorough medical, developmental, educational, and psychosocial evaluation is necessary to confirm the diagnosis. Several office visits, occasionally with more than one healthcare provider, may be necessary during the evaluation process.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      CONDITIONS THAT EXIST WITH ADHD",
"     </span>",
"    </p>",
"    <p>",
"     Other psychological and developmental disorders exist in as many as one-half of children with ADHD. These can be difficult to distinguish from ADHD because there are frequently overlapping symptoms. The most common coexisting disorders include learning disabilities, disruptive behavior disorders (oppositional defiant disorder and conduct disorder), and mood disorders (anxiety, depression, or bipolar disorder).",
"    </p>",
"    <p>",
"     Treatment for coexisting conditions may require medication. Behavioral or psychosocial treatments may also be recommended. A child with a coexisting condition usually requires the care of a specialist (eg, psychiatrist, child psychologist or developmental behavioral pediatrician, pediatric neuropsychologist, pediatric neurologist).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Learning disorders",
"     </span>",
"     &nbsp;&mdash;&nbsp;Learning disorders occur in 20 to 50 percent of children with ADHD, and may cause difficulty with performance in school. Parents should consult with the child&rsquo;s teacher",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     school counselor if they child is demonstrating difficulty with reading, spelling, or arithmetic.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Disruptive behavior disorders",
"     </span>",
"     &nbsp;&mdash;&nbsp;Disruptive behavior disorders include oppositional defiant disorder (ODD) and conduct disorder (CD), and affect up to 40 percent of people with ADHD. While all children and adolescents can exhibit disruptive behaviors at some point, those with ODD or CD behave in this way frequently and over a longer period of time than would normally be expected.",
"    </p>",
"    <p>",
"     ODD often causes a pattern of arguing with adults, frequent temper tantrums, and refusing to follow school or family rules. CD is a more severe form of ODD that includes a pattern of intentionally breaking the rules while trying to avoid being caught; lying or stealing; and aggressive behaviors that threaten or harm property, people, or animals.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Mood disorders",
"     </span>",
"     &nbsp;&mdash;&nbsp;Mood disorders include depression, anxiety, and bipolar (manic depressive) disorder. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/6/13413?source=see_link\">",
"      \"Patient information: Depression in adolescents (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"      \"Patient information: Bipolar disorder (manic depression) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHEN TO SEEK HELP",
"     </span>",
"    </p>",
"    <p>",
"     Parents who suspect that their child has ADHD should begin by talking to the child's teacher",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     school staff. This can help parents determine if the child has difficulties with behavior in more than one setting (eg, at home and at school).",
"    </p>",
"    <p>",
"     The next step is to make an appointment with the child's healthcare provider. The provider will evaluate the child and determine if further testing or evaluation is needed, and if ADHD or another condition is a possible cause of symptoms. Bringing school records to the appointment may help the provider to have a clearer understanding of the child's situation. More than one visit, occasionally with another clinician, is often necessary before a diagnosis is made.",
"    </p>",
"    <p>",
"     After the diagnosis is made and treatment begins, the parent, teacher, and healthcare provider will continue to monitor the child to ensure that treatment is effective and the diagnosis is correct. Referral to a developmental behavioral pediatrician or child psychiatrist may be recommended if improvements are not seen; further evaluation is sometimes required.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      ADHD TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of attention deficit hyperactivity disorder is discussed separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/53/35668?source=see_link\">",
"      \"Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your child's healthcare provider is the best source of information for questions and concerns related to your child's medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7376576\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7376583\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/32/11778?source=see_link\">",
"      Patient information: Attention deficit hyperactivity disorder (ADHD) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?37/47/38641?source=see_link\">",
"      Patient information: Learning disabilities (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7376608\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/53/35668?source=see_link\">",
"      Patient information: Treatment of attention deficit hyperactivity disorder in children (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/6/13413?source=see_link\">",
"      Patient information: Depression in adolescents (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/55/39796?source=see_link\">",
"      Patient information: Bipolar disorder (manic depression) (Beyond the Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7376624\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"     <br/>",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/18/26922?source=see_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Clinical features and evaluation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/19/14650?source=see_link\">",
"      Pharmacology of drugs used to treat attention deficit hyperactivity disorder in children and adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/39/34423?source=see_link\">",
"      Cardiac evaluation of patients receiving pharmacotherapy for attention deficit hyperactivity disorder",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/6/34922?source=see_link\">",
"      Long-term neurodevelopmental outcome of premature infants",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=see_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/57/32665?source=see_link\">",
"      Specific learning disabilities in children: Clinical features",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/6/35944?source=see_link\">",
"      Specific learning disabilities in children: Evaluation",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Children and Adults with Attention Deficit Hyperactivity Disorder",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.chadd.org/\">",
"      www.chadd.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Alliance for the Mentally Ill",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nami.org/\">",
"      www.nami.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Attention Deficit Disorder Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.add.org/\">",
"      www.add.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Mental Health",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nimh.nih.gov/health/publications/adhd-listing.shtml\">",
"      www.nimh.nih.gov/health/publications/adhd-listing.shtml",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The United States Department of Education",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ed.gov/about/offices/list/osers\">",
"      www.ed.gov/about/offices/list/osers",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The American Academy of Child and Adolescent Psychiatry",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.aacap.org/\">",
"      www.aacap.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Learning Disabilities Association of America",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.ldaamerica.org/aboutld/teachers/understanding/adhd.asp\">",
"      www.ldaamerica.org/aboutld/teachers/understanding/adhd.asp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"mobipreview.htm?33/8/33922/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?33/8/33922?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33922/abstract/1\">",
"      Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management, Wolraich M, et al. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics 2011; 128:1007.",
"     </a>",
"    </li>",
"    <li>",
"     Attention-deficit and disruptive behavior disorders. In: Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision, 4th, American Psychiatric Association, Washington, DC 2000. p.85.",
"    </li>",
"    <li>",
"     National Institute for Health and Clinical Excellence. Attention deficit hyperactivity disorder: Diagnosis and management of ADHD in children, young people and adults. 2008. file://www.nice.org.uk/CG72 (Accessed on October 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33922/abstract/4\">",
"      Pliszka S, AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2007; 46:894.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f33_8_33922=[""].join("\n");
var outline_f33_8_33922=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ATTENTION DEFICIT HYPERACTIVITY DISORDER OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           ADHD CAUSES",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           ADHD SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H8\">",
"           ADHD EVALUATION AND DIAGNOSIS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           CONDITIONS THAT EXIST WITH ADHD",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHEN TO SEEK HELP",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           ADHD TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f33_8_33923="Apical 5-chamber MV SAM in HCM";
var content_f33_8_33923=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F87655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F87655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 535px\">",
"   <div class=\"ttl\">",
"    Apical 5-chamber echocardiogram showing systolic anterior motion (SAM) of the mitral valve (MV) in a patient with hypertrophic cardiomyopathy (HCM)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 515px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apical 5-chamber transthoracic echocardiogram showing minimal systolic anterior motion (SAM) of the mitral valve under basal resting conditions (panel A) which is markedly worsening during exercise (panel B) resulting in mitral-septal contact and obstruction in the left ventricular outflow tract.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Maron MS, Olivotto I, Zenovich AG, et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006; 114:2232. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33923=[""].join("\n");
var outline_f33_8_33923=null;
var title_f33_8_33924="Radiation therapy for the management of painful bone metastases";
var content_f33_8_33924=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiation therapy for the management of painful bone metastases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33924/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33924/contributors\">",
"     Lisa A Kachnic, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33924/contributors\">",
"     Steven J DiBiase, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33924/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33924/contributors\">",
"     Brian Kavanagh, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33924/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33924/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/8/33924/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone metastases are a common manifestation of distant relapse from many types of solid cancers, especially those arising in the lung, breast, and prostate. As many as 80 percent of patients with solid tumors will develop painful bone metastases to the spine, pelvis, and extremities during the course of their illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The goals of palliative treatment of bone metastases are pain relief, preservation of function, and maintenance of skeletal integrity. When bone pain is limited to a single or a limited number of sites, local field external beam radiation therapy (RT) to the painful sites can provide pain relief in 80 to 90 percent of cases, with complete pain response obtained in 50 to 60 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/2\">",
"     2",
"    </a>",
"    ]. If symptomatic lesions are widespread, radiopharmaceuticals or hemibody radiation may provide useful palliative alternatives. Although treatment can be effective for patients with mild, moderate, or severe pain, early intervention may be useful in maintaining quality of life and minimizing side effects of analgesic medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of external beam and hemibody irradiation will be reviewed here. Other aspects of cancer pain management are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=see_link\">",
"     \"Cancer pain management: General principles and risk management for patients receiving opioids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTERNAL BEAM RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines from the American Society of Radiation Oncology (ASTRO) support treatment with a single fraction of radiation using a dose of 8 Gy to provide palliation for relief of pain from bone metastases.",
"   </p>",
"   <p>",
"    Based upon a systematic review of the literature, this approach improved patient convenience and was more cost effective compared with fractionated schedules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/2\">",
"     2",
"    </a>",
"    ]. The use of a single 8 Gy fraction for pain relief is also supported by a second systematic review of the literature that looked at different doses of radiation administered as a single fraction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/4\">",
"     4",
"    </a>",
"    ]. That review also concluded that a dose of 8 Gy was more effective than lower doses in providing pain relief.",
"   </p>",
"   <p>",
"    Retreatment was necessary in approximately 20 percent of patients treated with a single fraction compared with 8 percent in those initially managed with a fractionated regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/2\">",
"     2",
"    </a>",
"    ]. There was no evidence that the use of a single fraction regimen was associated with an increase in acute or late toxicity.",
"   </p>",
"   <p>",
"    The effectiveness of a single fraction of 8 Gy compared with longer fractionated courses is illustrated by the three largest randomized trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a Dutch multicenter trial, in which 1171 patients with painful bone metastases were randomly assigned to 8 Gy in a single dose or 24 Gy in six fractions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/5,6\">",
"       5,6",
"      </a>",
"      ]. The palliative benefit was similar in both groups (overall pain relief in 72 and 69 percent of patients, respectively), as was the time to response (median three weeks in both groups). There was no difference in treatment-related toxicity. However, retreatment was required by significantly more patients treated with a single fraction (25 versus 7 percent).",
"     </li>",
"     <li>",
"      In the Radiation Therapy Oncology Group (RTOG) trial 9714, 949 patients with prostate or breast cancer and painful bone metastases were randomly assigned to 8 Gy in a single fraction or 30 Gy in 10 fractions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/7\">",
"       7",
"      </a>",
"      ]. Patients with evidence of cauda equina syndrome or epidural spinal cord compression were excluded. There were no significant differences in the rates for complete and partial pain relief (overall 66 percent in each group), the use of narcotics, or the incidence of subsequent pathologic fractures. However, patients treated with a single fraction were twice as likely to require retreatment (18 versus 9 percent).",
"     </li>",
"     <li>",
"      A British trial randomly assigned 765 patients with painful bone metastases to 8 Gy as a single fraction, 20 Gy in five fractions, or 30 Gy in 10 fractions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/8\">",
"       8",
"      </a>",
"      ]. With median 12 month follow-up, there were no differences in any of the pain end points among the three groups (78 percent overall response rate with either single dose or multidose schedules); there was no difference in time to response between the regimens (median less than one month in those responding). Patients treated with a single fraction were twice as likely to require reirradiation of the same site, but the majority could be successfully retreated with a single fraction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these results, and in the interest of patient convenience, a single fraction of 8 Gy for the management of painful bone metastases should be strongly considered. An international trial initiated by the National Cancer Institute of Canada (NCIC SC20) is examining the efficacy of two different fractionation schedules for the retreatment of bone metastases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although radiation therapy is effective in partially or completely relieving pain in a majority of patients with bone metastases, a transient worsening of pain may occur in some patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/10\">",
"     10",
"    </a>",
"    ]. This typically occurs in the first few days after RT, and the flare in pain generally lasts one to two days.",
"   </p>",
"   <p>",
"    Surgical fixation may be indicated prior to EBRT to decrease pain and facilitate rehabilitation in symptomatic bone metastases causing a pathologic fracture involving the long bones or other weight-bearing bones. In other cases, prophylactic fixation to prevent pathologic fractures may be recommended prior to EBRT. Patients with inoperable fractures and those who are physically debilitated may achieve pain relief from palliative EBRT alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STEREOTACTIC RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiation therapy (SBRT) is a technique that utilizes precisely targeted radiation to a tumor while minimizing radiation to adjacent normal tissue. This targeting allows treatment of small- or moderate-sized tumors in either a single or limited number of dose fractions.",
"   </p>",
"   <p>",
"    Stereotactic body RT (SBRT) may have a role in treating selected patients with painful bone metastases. SBRT may be particularly useful for treating the spine, where there is a significant concern about normal tissue toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link&amp;anchor=H10#H10\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Spinal and paraspinal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349027233\">",
"    <span class=\"h1\">",
"     REIRRADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reirradiation may be an option for patients with painful bone metastases if the initial treatment fails to adequately relieve bone pain or there is a subsequent relapse after an initial response. There are only limited data on the optimal indications and dosing for reirradiation.",
"   </p>",
"   <p>",
"    A meta-analysis of seven studies that included 2694 patients who were initially treated with RT for painful bone metastases found that reirradiation was subsequently used in 527 (20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/12\">",
"     12",
"    </a>",
"    ]. Retreatment produced some benefit in terms of pain relief in 58 percent (95% CI 49&ndash;67 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     RADIOPHARMACEUTICALS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone-targeting radioisotopes (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26851?source=see_link\">",
"     strontium-89",
"    </a>",
"    [89Sr], samarium-153 lexidronam [153Sm], radium-223) localize to areas of osteoblastic activity, and are indicated for the treatment of bone pain in patients with predominantly osteoblastic metastases. Because these agents are systemically administered, they are most appropriate for patients with multiple painful lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link&amp;anchor=H261305508#H261305508\">",
"     \"Management of bone metastases in advanced prostate cancer\", section on 'Bone-targeted radiopharmaceuticals'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1296906686\">",
"    <span class=\"h1\">",
"     OSTEOCLAST INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoclast inhibitors, including bisphosphonates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/53/21335?source=see_link\">",
"     denosumab",
"    </a>",
"    slow or reverse the progression of skeletal metastases. These agents are widely used in the treatment of patients with bone metastases from breast cancer, multiple myeloma, and other solid tumors, including prostate cancer and non-small cell lung cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H865040088\">",
"    <span class=\"h1\">",
"     HEMIBODY IRRADIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemibody irradiation refers to treating a large portion of the body with external beam irradiation and can provide rapid pain relief when multiple sites of symptomatic bone metastases are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/2,13\">",
"     2,13",
"    </a>",
"    ]. The use of hemibody irradiation has largely been replaced by the administration of radiopharmaceuticals, which offer a similar degree of pain relief and may be associated with less toxicity. Hemibody irradiation may retain a role when access to radiopharmaceuticals is limited.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1312968849\">",
"    <span class=\"h1\">",
"     FOCUSED ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Magnetic resonance guided focused ultrasound (ExAblate) is an approved device to provide palliation for painful bone metastases in patients who have either failed on standard RT or are not candidates for RT. The focused ultrasound waves raise the temperature at the imaged focal point and thus produce thermal tissue ablation. The regulatory approval of this device was based upon an international multicenter trial that demonstrated the activity and safety of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33924/abstract/14\">",
"     14",
"    </a>",
"    ], but the results of this trial have not been published in a peer reviewed journal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with a single or limited number of areas of painful bone metastases, we recommend external beam radiation therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'External beam RT'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest using a single fraction of 8 Gy to the involved area (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). This approach provides equal palliation with improved patient convenience and cost effectiveness compared with fractionated schedules, although retreatment is needed more frequently.",
"     </li>",
"     <li>",
"      For patients with a relatively long life expectancy, a fractionated regimen (such as 30 Gy in ten fractions or 20 Gy in five fractions) may also be considered.",
"     </li>",
"     <li>",
"      Reirradiation is indicated if there is an incomplete response to initial treatment or if severe pain recurs. (See",
"      <a class=\"local\" href=\"#H349027233\">",
"       'Reirradiation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical fixation may be indicated prior to the institution of radiation therapy for bone metastases involving the long bones or other weight bearing bones to treat or prevent a pathologic fracture. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=see_link\">",
"       \"Psychological, rehabilitative, and integrative therapies for cancer pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with widespread painful bone metastases who cannot be effectively managed with external beam radiation therapy, either radiopharmaceuticals or hemibody irradiation may provide meaningful palliation. (See",
"      <a class=\"local\" href=\"#H865040088\">",
"       'Hemibody irradiation'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=see_link&amp;anchor=H261305508#H261305508\">",
"       \"Management of bone metastases in advanced prostate cancer\", section on 'Bone-targeted radiopharmaceuticals'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/1\">",
"      Nielsen OS. Palliative radiotherapy of bone metastases: there is now evidence for the use of single fractions. Radiother Oncol 1999; 52:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/2\">",
"      Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/3\">",
"      Kirou-Mauro A, Hird A, Wong J, et al. Is response to radiotherapy in patients related to the severity of pretreatment pain? Int J Radiat Oncol Biol Phys 2008; 71:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/4\">",
"      Dennis K, Makhani L, Zeng L, et al. Single fraction conventional external beam radiation therapy for bone metastases: a systematic review of randomised controlled trials. Radiother Oncol 2013; 106:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/5\">",
"      Steenland E, Leer JW, van Houwelingen H, et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999; 52:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/6\">",
"      van der Linden YM, Lok JJ, Steenland E, et al. Single fraction radiotherapy is efficacious: a further analysis of the Dutch Bone Metastasis Study controlling for the influence of retreatment. Int J Radiat Oncol Biol Phys 2004; 59:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/7\">",
"      Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 2005; 97:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/8\">",
"      8 Gy single fraction radiotherapy for the treatment of metastatic skeletal pain: randomised comparison with a multifraction schedule over 12 months of patient follow-up. Bone Pain Trial Working Party. Radiother Oncol 1999; 52:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/9\">",
"      Chow E, Hoskin PJ, Wu J, et al. A phase III international randomised trial comparing single with multiple fractions for re-irradiation of painful bone metastases: National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) SC 20. Clin Oncol (R Coll Radiol) 2006; 18:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/10\">",
"      Hird A, Chow E, Zhang L, et al. Determining the incidence of pain flare following palliative radiotherapy for symptomatic bone metastases: results from three canadian cancer centers. Int J Radiat Oncol Biol Phys 2009; 75:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/11\">",
"      Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol 2012; 13:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/12\">",
"      Huisman M, van den Bosch MA, Wijlemans JW, et al. Effectiveness of reirradiation for painful bone metastases: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2012; 84:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33924/abstract/13\">",
"      Salazar OM, Sandhu T, da Motta NW, et al. Fractionated half-body irradiation (HBI) for the rapid palliation of widespread, symptomatic, metastatic bone disease: a randomized Phase III trial of the International Atomic Energy Agency (IAEA). Int J Radiat Oncol Biol Phys 2001; 50:765.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.accessdata.fda.gov/cdrh_docs/pdf11/P110039b.pdf (Accessed on November 30, 2012).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2805 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-201.211.0.116-EC95FD50DF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33924=[""].join("\n");
var outline_f33_8_33924=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTERNAL BEAM RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STEREOTACTIC RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349027233\">",
"      REIRRADIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      RADIOPHARMACEUTICALS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1296906686\">",
"      OSTEOCLAST INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H865040088\">",
"      HEMIBODY IRRADIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1312968849\">",
"      FOCUSED ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43704?source=related_link\">",
"      Cancer pain management: General principles and risk management for patients receiving opioids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/8/36999?source=related_link\">",
"      Management of bone metastases in advanced prostate cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32170?source=related_link\">",
"      Psychological, rehabilitative, and integrative therapies for cancer pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_8_33925="Oxygenation and mechanisms of hypoxemia";
var content_f33_8_33925=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Oxygenation and mechanisms of hypoxemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33925/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33925/contributors\">",
"     Arthur C Theodore, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33925/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33925/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33925/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33925/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/8/33925/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The process of taking oxygen from the inspired air and using it to sustain aerobic cellular metabolism throughout the body can be conceptualized as having three steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygenation is the process of oxygen diffusing passively from the alveolus to the pulmonary capillary, where it binds to hemoglobin in red blood cells or dissolves into the plasma. Insufficient oxygenation is termed hypoxemia.",
"     </li>",
"     <li>",
"      Oxygen delivery is the rate of oxygen transport from the lungs to the peripheral tissues.",
"     </li>",
"     <li>",
"      Oxygen consumption is the rate at which oxygen is removed from the blood for use by the tissues.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this topic review, measures of oxygenation and mechanisms of hypoxemia are discussed. Oxygen delivery and consumption are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31430?source=see_link\">",
"     \"Oxygen delivery and consumption\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MEASURES OF OXYGENATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous ways to measure whether oxygenation is impaired and at risk of being insufficient to meet the metabolic requirements of the peripheral tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Arterial oxygen saturation (SaO2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the oxygen that diffuses from the alveolus to the pulmonary capillary binds to hemoglobin in red blood cells. The arterial oxygen saturation (SaO",
"    <sub>",
"     2",
"    </sub>",
"    ) is the proportion of red blood cells whose hemoglobin is bound to oxygen. It is most commonly measured noninvasively by pulse oximetry, but can also be measured by arterial blood gas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9736?source=see_link\">",
"     \"Pulse oximetry\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypoxia is defined as a condition where the oxygen supply is inadequate either to the body as a whole (general hypoxia) or to a specific region (tissue hypoxia). Abnormal SaO",
"    <sub>",
"     2",
"    </sub>",
"    has not been defined because a threshold below which tissue hypoxia occurs has not been identified. This reflects with multifactorial nature of tissue hypoxia. It seems reasonable to consider a resting SaO",
"    <sub>",
"     2",
"    </sub>",
"    &le;95 percent or exercise desaturation &ge;5 percent abnormal, although these values should not be considered in isolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, a resting SaO",
"    <sub>",
"     2",
"    </sub>",
"    of 95 percent could be abnormal if a patient previously had a resting SaO",
"    <sub>",
"     2",
"    </sub>",
"    of 99 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Arterial oxygen tension (PaO2)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small amount of the oxygen that diffuses from the alveolus to the pulmonary capillary dissolves into the plasma. The arterial oxygen tension (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) is the amount of oxygen dissolved in the plasma, which is measured by arterial blood gas. Similar to oxygen saturation, an abnormal PaO",
"    <sub>",
"     2",
"    </sub>",
"    has not been defined because a threshold below which tissue hypoxia occurs has not been identified. However, it seems reasonable to consider a PaO",
"    <sub>",
"     2",
"    </sub>",
"    &lt;80 mmHg abnormal, although the value should not be considered in isolation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15894?source=see_link\">",
"     \"Arterial blood gases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     A-a oxygen gradient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alveolar to arterial (A-a) oxygen gradient is a common measure of oxygenation. It is the difference between the amount of the oxygen in the alveoli (ie, the alveolar oxygen tension [PAO",
"    <sub>",
"     2",
"    </sub>",
"    ]) and the amount of oxygen dissolved in the plasma (PaO",
"    <sub>",
"     2",
"    </sub>",
"    ) (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?30/51/31539?source=see_link\">",
"     calculator 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    &nbsp;A-a oxygen gradient = PAO",
"    <sub>",
"     2",
"    </sub>",
"    - PaO",
"    <sub>",
"     2",
"    </sub>",
"    .",
"   </p>",
"   <p>",
"    PaO",
"    <sub>",
"     2",
"    </sub>",
"    is measured by arterial blood gas, while PAO",
"    <sub>",
"     2",
"    </sub>",
"    is calculated using the alveolar gas equation:",
"   </p>",
"   <p>",
"    &nbsp;PAO",
"    <sub>",
"     2",
"    </sub>",
"    &nbsp;= &nbsp;(FiO",
"    <sub>",
"     2",
"    </sub>",
"    &nbsp;x &nbsp;[Patm &nbsp;- &nbsp;PH",
"    <sub>",
"     2",
"    </sub>",
"    O]) - &nbsp;(PaCO",
"    <sub>",
"     2",
"    </sub>",
"    &nbsp;&divide; &nbsp;R)",
"   </p>",
"   <p>",
"    where FiO",
"    <sub>",
"     2",
"    </sub>",
"    is the fraction of inspired oxygen (0.21 at room air), Patm is the atmospheric pressure (760 mmHg at sea level), PH",
"    <sub>",
"     2",
"    </sub>",
"    O is the partial pressure of water (47 mmHg at 37 degrees C), PaCO",
"    <sub>",
"     2",
"    </sub>",
"    is the arterial carbon dioxide tension, and R is the respiratory quotient. The respiratory quotient is approximately 0.8 at steady state, but varies according to the relative utilization of carbohydrate, protein, and fat.",
"   </p>",
"   <p>",
"    The A-a gradient calculated using this alveolar gas equation may deviate from the true gradient by up to 10 mmHg. This reflects the equation's simplification from the more rigorous full calculation and the imprecision of several independent variables (eg, FiO",
"    <sub>",
"     2",
"    </sub>",
"    and R).",
"   </p>",
"   <p>",
"    The normal A-a gradient varies with age and can be estimated from the following equation, assuming the patient is breathing room air (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?30/51/31539?source=see_link\">",
"     calculator 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    A-a gradient = 2.5 + 0.21 x age in years",
"   </p>",
"   <p>",
"    The A-a gradient increases with higher FiO",
"    <sub>",
"     2",
"    </sub>",
"    . When a patient receives a high FiO",
"    <sub>",
"     2",
"    </sub>",
"    , both PAO",
"    <sub>",
"     2",
"    </sub>",
"    and PaO",
"    <sub>",
"     2",
"    </sub>",
"    increase. However, the PAO",
"    <sub>",
"     2",
"    </sub>",
"    increases disproportionately, causing the A-a gradient to increase. In one series, the A-a gradient in men breathing air and 100 percent oxygen varied from 8 to 82 mmHg in patients younger than 40 years of age and from 3 to 120 mmHg in patients older than 40 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     PaO2/FiO2 ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    ratio is another common measure of oxygenation. A normal",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    ratio is 300 to 500 mmHg, with values less than 300 mmHg indicating abnormal gas exchange and values less than 200 mmHg indicates severe hypoxemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/5\">",
"     5",
"    </a>",
"    ]. As an example, a patient whose PaO",
"    <sub>",
"     2",
"    </sub>",
"    is 60 mmHg while receiving an FiO",
"    <sub>",
"     2",
"    </sub>",
"    of 0.50 (ie, 50 percent) has a",
"    <span class=\"nowrap\">",
"     PaO",
"     <sub>",
"      2",
"     </sub>",
"     /FiO",
"     <sub>",
"      2",
"     </sub>",
"    </span>",
"    ratio of 120 mmHg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     A-a oxygen ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alveolar to arterial (A-a) oxygen ratio is determined by dividing the PaO",
"    <sub>",
"     2",
"    </sub>",
"    by the PAO",
"    <sub>",
"     2",
"    </sub>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    &nbsp;A-a oxygen ratio = PaO",
"    <sub>",
"     2",
"    </sub>",
"    &divide; PAO",
"    <sub>",
"     2",
"    </sub>",
"   </p>",
"   <p>",
"    The A-a oxygen ratio is commonly used to predict the change in PaO",
"    <sub>",
"     2",
"    </sub>",
"    that will result when the FiO",
"    <sub>",
"     2",
"    </sub>",
"    is changed. Its lower limit of normal is 0.77-0.82 and it is most reliable when the FiO",
"    <sub>",
"     2",
"    </sub>",
"    is less than 0.55 (ie, 55 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oxygenation index",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oxygenation index (OI) is most commonly used in neonates with persistent pulmonary hypertension of the newborn to determine the severity of hypoxemia and to guide the timing of interventions, such as inhaled nitric oxide&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. The OI is calculated as follows (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?13/49/14098?source=see_link\">",
"     calculator 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    &nbsp;OI &nbsp;= &nbsp;[mean airway pressure &nbsp;x &nbsp;FiO",
"    <sub>",
"     2",
"    </sub>",
"    &nbsp;&divide; &nbsp;PaO",
"    <sub>",
"     2",
"    </sub>",
"    ] &nbsp;x &nbsp;100",
"   </p>",
"   <p>",
"    A high OI (eg, &ge;25) indicates severe hypoxemic respiratory failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=see_link\">",
"     \"Persistent pulmonary hypertension of the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MECHANISMS OF HYPOXEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoxemia is defined as a decrease in the partial pressure of oxygen in the blood. Hypoxemia does not necessarily indicate tissue hypoxia. It can be caused by hypoventilation, ventilation-perfusion mismatch, right-to-left shunt, diffusion impairment, or reduced inspired oxygen tension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hypoventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both arterial (PaCO",
"    <sub>",
"     2",
"    </sub>",
"    ) and alveolar (PACO",
"    <sub>",
"     2",
"    </sub>",
"    ) carbon dioxide tension increase during hypoventilation, which causes the alveolar oxygen tension (PAO",
"    <sub>",
"     2",
"    </sub>",
"    ) to decrease. As a result, diffusion of oxygen from the alveolus to the pulmonary capillary declines. The net effect is hypoxemia.",
"   </p>",
"   <p>",
"    Hypoxemia due to pure hypoventilation can be identified by two characteristics. First, it readily corrects with a small increase in the fraction of inspired oxygen (FiO",
"    <sub>",
"     2",
"    </sub>",
"    ). Second, the A-a gradient is usually normal. An exception exists when the hypoventilation is prolonged because atelectasis can occur, which will increase the A-a gradient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33925/abstract/11\">",
"     11",
"    </a>",
"    ]. Abnormalities that cause pure hypoventilation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CNS depression, such as drug overdose, structural CNS lesions, or ischemic CNS lesions that impact the respiratory center",
"     </li>",
"     <li>",
"      Obesity hypoventilation (Pickwickian) syndrome",
"     </li>",
"     <li>",
"      Impaired neural conduction, such as amyotrophic lateral sclerosis, Guillain-Barr&eacute; syndrome, high cervical spine injury, phrenic nerve paralysis, or aminoglycoside blockade",
"     </li>",
"     <li>",
"      Muscular weakness, such as myasthenia gravis, idiopathic diaphragmatic paralysis, polymyositis, muscular dystrophy, or severe hypothyroidism",
"     </li>",
"     <li>",
"      Poor chest wall elasticity, such as a flail chest or kyphoscoliosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     V/Q mismatch",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventilation-perfusion",
"    <span class=\"nowrap\">",
"     (V/Q)",
"    </span>",
"    mismatch refers to an imbalance of blood flow and ventilation. It causes the composition of alveolar gas to vary among lung regions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lung regions with low ventilation compared to perfusion will have a low alveolar oxygen content and high CO",
"      <sub>",
"       2",
"      </sub>",
"      content",
"     </li>",
"     <li>",
"      Lung regions with high ventilation compared to perfusion will have a low CO",
"      <sub>",
"       2",
"      </sub>",
"      content and high oxygen content",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the normal lung, there is",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch because perfusion and ventilation are heterogeneous. Both ventilation and perfusion are greater in the bases than in the apices. However, the difference between apical and basilar ventilation is smaller than the difference between apical and basilar perfusion. As a result, the",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    ratio is higher in the apices than in the bases.",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch is responsible for the normal A-a gradient.",
"   </p>",
"   <p>",
"    In the diseased lung,",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch increases because heterogeneity of both ventilation and perfusion worsen. The net effect is hypoxemia. Hypoxemia due to",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch can be corrected with low to moderate flow supplemental oxygen and is characterized by an increased A-a gradient. Common causes of hypoxemia due to",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch include obstructive lung diseases, pulmonary vascular diseases, and interstitial diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Right-to-left shunt",
"    </span>",
"    &nbsp;&mdash;&nbsp;A right-to-left shunt exists when blood passes from the right to the left side of the heart without being oxygenated. There are two types of right-to-left shunts:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomic shunts exist when the alveoli are bypassed. Examples include intracardiac shunts, pulmonary arteriovenous malformations (AVMs), and hepatopulmonary syndrome.",
"     </li>",
"     <li>",
"      Physiologic shunts exist when non-ventilated alveoli are perfused. Examples include atelectasis and diseases with alveolar filling (eg, pneumonia, acute respiratory distress syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Right-to-left shunts cause extreme",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch, with a",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    ratio of zero in some lung regions. The net effect is hypoxemia, which is difficult to correct with supplemental oxygen.",
"   </p>",
"   <p>",
"    The degree of shunt can be quantified from the shunt equation (",
"    <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/6/1123?source=see_link\">",
"     calculator 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    &nbsp;",
"    <span class=\"nowrap\">",
"     Qs/Qt",
"    </span>",
"    &nbsp;= &nbsp;(CcO",
"    <sub>",
"     2",
"    </sub>",
"    &nbsp;- &nbsp;CaO",
"    <sub>",
"     2",
"    </sub>",
"    ) &nbsp;&divide; &nbsp;(CcO",
"    <sub>",
"     2",
"    </sub>",
"    &nbsp;- &nbsp;CvO",
"    <sub>",
"     2",
"    </sub>",
"    )",
"   </p>",
"   <p>",
"    where",
"    <span class=\"nowrap\">",
"     Qs/Qt",
"    </span>",
"    is the shunt fraction, CcO",
"    <sub>",
"     2",
"    </sub>",
"    is the end-capillary oxygen content, CaO",
"    <sub>",
"     2",
"    </sub>",
"    is the arterial oxygen content, and CvO",
"    <sub>",
"     2",
"    </sub>",
"    is the mixed venous oxygen content. CaO",
"    <sub>",
"     2",
"    </sub>",
"    and CvO",
"    <sub>",
"     2",
"    </sub>",
"    are calculated from arterial and mixed venous blood gas measurements, respectively. CcO",
"    <sub>",
"     2",
"    </sub>",
"    is estimated from the PAO",
"    <sub>",
"     2",
"    </sub>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31430?source=see_link&amp;anchor=H2#H2\">",
"     \"Oxygen delivery and consumption\", section on 'Definitions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Diffusion limitation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diffusion limitation exists when the movement of oxygen from the alveolus to the pulmonary capillary is impaired. It is usually a consequence of alveolar",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    interstitial inflammation and fibrosis, such as that due to interstitial lung disease. In such diseases, diffusion limitation usually coexists with",
"    <span class=\"nowrap\">",
"     V/Q",
"    </span>",
"    mismatch, which makes the relative contribution of each to the patient's hypoxemia uncertain.",
"   </p>",
"   <p>",
"    Diffusion limitation is characterized by exercise-induced or -exacerbated hypoxemia. This is illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      During rest, blood traverses the lung relatively slowly. Thus, there is usually sufficient time for oxygenation to occur even if diffusion limitation exists.",
"     </li>",
"     <li>",
"      During exercise, cardiac output increases and blood traverses the lung more quickly. As a result, there is less time for oxygenation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the healthy individuals, several compensatory mechanisms occur. Pulmonary capillaries dilate, which increases the surface area available for gas exchange by perfusing additional regions of lung. PAO",
"      <sub>",
"       2",
"      </sub>",
"      also increases, which promotes oxygen diffusion by increasing the oxygen gradient from the alveolus to the artery. The net effect is that full oxygenation is sustained.",
"     </li>",
"     <li>",
"      In patients with diffusion limitation, there is insufficient time for oxygenation to occur. In addition, most such patients have parenchymal destruction, which renders it impossible to recruit additional surface area for gas exchange. The net effect is measurable hypoxemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Reduced inspired oxygen tension",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inspired oxygen tension (PiO",
"    <sub>",
"     2",
"    </sub>",
"    ) is a component of the alveolar gas equation that was described above. It can be determined by the equation:",
"   </p>",
"   <p>",
"    PiO",
"    <sub>",
"     2",
"    </sub>",
"    = FiO",
"    <sub>",
"     2",
"    </sub>",
"    x (Patm - PH",
"    <sub>",
"     2",
"    </sub>",
"    O)",
"   </p>",
"   <p>",
"    where FiO",
"    <sub>",
"     2",
"    </sub>",
"    is the fraction of inspired oxygen (0.21 at room air), Patm is the atmospheric pressure (760 mmHg at sea level), and PH",
"    <sub>",
"     2",
"    </sub>",
"    O is the partial pressure of water (47 mmHg at 37 degrees C).",
"   </p>",
"   <p>",
"    Reduction of the PiO",
"    <sub>",
"     2",
"    </sub>",
"    will decrease the PAO",
"    <sub>",
"     2",
"    </sub>",
"    . This impairs oxygen diffusion by decreasing the oxygen gradient from the alveolus to the artery. The net effect is hypoxemia. A reduced PiO",
"    <sub>",
"     2",
"    </sub>",
"    is most commonly associated with high altitude.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygenation is the process of oxygen diffusing passively from the alveolus to the pulmonary capillary, where it binds to hemoglobin in red blood cells or dissolves into the plasma. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are numerous ways to determine whether oxygenation is impaired and at risk of being insufficient to meet the metabolic requirements of the peripheral tissues. The arterial oxygen saturation (SaO",
"      <sub>",
"       2",
"      </sub>",
"      ), arterial oxygen tension (PaO",
"      <sub>",
"       2",
"      </sub>",
"      ), alveolar to arterial (A-a) oxygen gradient, and the",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      ratio are common measures. Alternatively, the A-a oxygen ratio and the oxygenation index can be used. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Measures of oxygenation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A low partial pressure of oxygen in the blood is termed hypoxemia. Causes of hypoxemia include hypoventilation, ventilation-perfusion",
"      <span class=\"nowrap\">",
"       (V/Q)",
"      </span>",
"      mismatch, right-to-left shunts, diffusion limitation, and reduced inspired oxygen tension. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Mechanisms of hypoxemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/1\">",
"      American Thoracic Society, American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003; 167:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/2\">",
"      Hansen JE, Sue DY, Wasserman K. Predicted values for clinical exercise testing. Am Rev Respir Dis 1984; 129:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/3\">",
"      Mellemgaard K. The alveolar-arterial oxygen difference: its size and components in normal man. Acta Physiol Scand 1966; 67:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/4\">",
"      Kanber GJ, King FW, Eshchar YR, Sharp JT. The alveolar-arterial oxygen gradient in young and elderly men during air and oxygen breathing. Am Rev Respir Dis 1968; 97:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/5\">",
"      Covelli, HD, Nessan, VJ, Tuttle, WK. Oxygen derived variables in acute respiratory failure. Crit Care Med 1983; 8:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/6\">",
"      Gilbert R, Keighley JF. The arterial-alveolar oxygen tension ratio. An index of gas exchange applicable to varying inspired oxygen concentrations. Am Rev Respir Dis 1974; 109:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/7\">",
"      Peris LV, Boix JH, Salom JV, et al. Clinical use of the arterial/alveolar oxygen tension ratio. Crit Care Med 1983; 11:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/8\">",
"      Trachsel D, McCrindle BW, Nakagawa S, Bohn D. Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure. Am J Respir Crit Care Med 2005; 172:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/9\">",
"      American Academy of Pediatrics. Committee on Fetus and Newborn. Use of inhaled nitric oxide. Pediatrics 2000; 106:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/10\">",
"      Rodr&iacute;guez-Roisin R, Roca J. Mechanisms of hypoxemia. Intensive Care Med 2005; 31:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33925/abstract/11\">",
"      Williams AJ. ABC of oxygen: assessing and interpreting arterial blood gases and acid-base balance. BMJ 1998; 317:1213.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1647 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-1420615FBC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33925=[""].join("\n");
var outline_f33_8_33925=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MEASURES OF OXYGENATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Arterial oxygen saturation (SaO2)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Arterial oxygen tension (PaO2)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      A-a oxygen gradient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PaO2/FiO2 ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      A-a oxygen ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oxygenation index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MECHANISMS OF HYPOXEMIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hypoventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      V/Q mismatch",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Right-to-left shunt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Diffusion limitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Reduced inspired oxygen tension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?30/51/31539?source=related_link\" title=\"calculator 1\">",
"      Calculator: A-a gradient (alveolar-arterial gradient; AaG)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?13/49/14098?source=related_link\" title=\"calculator 2\">",
"      Calculator: Oxygenation index",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"mobipreview.htm?1/6/1123?source=related_link\" title=\"calculator 3\">",
"      Calculator: Right to Left Shunt Fraction Qs/Qt",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/33/15894?source=related_link\">",
"      Arterial blood gases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/44/31430?source=related_link\">",
"      Oxygen delivery and consumption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27225?source=related_link\">",
"      Persistent pulmonary hypertension of the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_8_33926="Temporal triangular alopecia";
var content_f33_8_33926=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F87471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F87471&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Temporal triangular alopecia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A triangular patch with a paucity of terminal hair is present on the temporal scalp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33926=[""].join("\n");
var outline_f33_8_33926=null;
var title_f33_8_33927="Eisenmenger syndrome anatomy and physiology";
var content_f33_8_33927=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70502&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Eisenmenger's syndrome anatomy and physiology",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 711px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Eisenmenger syndrome is the triad of systemic-to-pulmonary cardiovascular communication, pulmonary arterial disease, and cyanosis. Pulmonary arterial disease develops as a consequence of increased pulmonary blood flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33927=[""].join("\n");
var outline_f33_8_33927=null;
var title_f33_8_33928="Cafe-au-lait macule 1";
var content_f33_8_33928=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73651&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 507px\">",
"   <div class=\"ttl\">",
"    Caf&eacute; au lait macules",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 487px; height: 475px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple caf&eacute; au lait macules were present on this young boy with neurofibromatosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fleisher GR, Ludwig S, Baskin MN. Atlas of Pediatric Emergency Medicine, Lippincott Williams &amp; Wilkins, Philadelphia 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33928=[""].join("\n");
var outline_f33_8_33928=null;
var title_f33_8_33929="Postconcussion syndrome";
var content_f33_8_33929=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Postconcussion syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33929/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33929/contributors\">",
"     Randolph W Evans, MD, FAAN",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33929/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33929/contributors\">",
"     Michael J Aminoff, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33929/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33929/contributors\">",
"     Janet L Wilterdink, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/8/33929/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postconcussion syndrome (PCS) is a common sequelae of traumatic brain injury (TBI), and it is a symptom complex that includes headache, dizziness, neuropsychiatric symptoms, and cognitive impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/1\">",
"     1",
"    </a>",
"    ]. PCS is most often described in the setting of mild TBI, but it may also occur after moderate and severe TBI, and similar symptoms are described after whiplash injuries as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/2\">",
"     2",
"    </a>",
"    ]. Loss of consciousness does not have to occur for PCS to develop.",
"   </p>",
"   <p>",
"    PCS is controversial, especially in its protracted form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/3\">",
"     3",
"    </a>",
"    ]. The symptoms are vague, subjective, and common in the general population. The affected patient population is heterogeneous with varying degrees of injury to the head and brain. Individual patient characteristics may alter the expression of the injury. The underlying pathophysiology is undefined. Test results may or may not be abnormal; when present, test abnormalities do not follow a consistently defined pattern.",
"   </p>",
"   <p>",
"    Mild TBI results after blunt force, nonpenetrating head trauma, and it is most often defined as mild by a Glasgow Coma Scale (GCS) score of 13 to 15, 30 minutes after head injury (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ). Concussion is a subset of mild TBI, and it is a trauma-induced alteration in mental status that may or may not involve loss of consciousness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/4\">",
"     4",
"    </a>",
"    ]. This topic will discuss the pathophysiology, clinical features, diagnosis, and management of PCS. The acute presentation and management and other sequelae of concussion and mild TBI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link\">",
"     \"Concussion and mild traumatic brain injury\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12906?source=see_link\">",
"     \"Minor head trauma in infants and children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thirty to 80 percent of patients with mild to moderate brain injury will experience some symptoms of postconcussion syndrome (PCS). This wide range of reported incidence reflects variabilities in the patient population studied and the criteria by which a diagnosis of PCS is made, either using individual symptoms or defined clinical criteria. Two clinical criteria, the International Classification of Diseases, ICD-10 and the DSM-IV, are commonly used and give widely different results, even within the same patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies have tried to associate the severity of brain injury with PCS among patients with mild traumatic brain injury (TBI) using a variety of measures including the Glasgow Coma Scale (GCS) (",
"    <a class=\"graphic graphic_table graphicRef81854 \" href=\"mobipreview.htm?28/62/29676\">",
"     table 1",
"    </a>",
"    ), the duration of loss of consciousness or post-traumatic amnesia, and the presence or extent of visualized abnormalities on CT or MRI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/2,5-8\">",
"     2,5-8",
"    </a>",
"    ]. Overall, the severity of injury does not clearly correlate with the risk of PCS.",
"   </p>",
"   <p>",
"    Cohort studies of patients with mild and moderate TBI have consistently found that female gender and increasing age are risk factors for PCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/5,6,9,10\">",
"     5,6,9,10",
"    </a>",
"    ]. While the nature of the head injury has not been systematically studied as a risk factor, some studies suggest that patients with a sports-related concussion have a better natural history than those with mild TBI resulting from motor vehicle accident, fall, or assault [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/11\">",
"     11",
"    </a>",
"    ]. This may reflect a different severity of the physical",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    psychosocial impact of the injury,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a different premorbid predisposition to PCS. This may also contribute to the gender differences, as the relative preponderance of accident and assault versus sports injury as a cause of TBI may be higher in women than men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are different theories for the pathogenesis of postconcussion syndrome (PCS). Some hold that the disorder is a structural and biochemical one resulting directly from the brain injury; others postulate a psychogenic origin. It is possible, even likely, that both of these contribute; in particular, these may have a different impact on different symptoms and at different times in the course of the syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Persistent postconcussion syndrome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurobiologic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of structural and biochemical changes have been documented in animal models of head injury and in human neuropathological studies. These are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link&amp;anchor=H4#H4\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Pathophysiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Physiologic and functional neuroimaging (SPECT, PET and functional MRI) also document more extensive areas of abnormality than is seen on CT, supporting a role for structural or physiologic brain injury in the production of PCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/7,13-21\">",
"     7,13-21",
"    </a>",
"    ]. However, many of these neuroimaging findings are not specific to head injury and are also noted in patients with migraine and depression. Also, studies do not consistently show a relationship between the extent of abnormalities seen on these studies and the degree of impairment or severity of symptoms experienced by the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/16,18,22,23\">",
"     16,18,22,23",
"    </a>",
"    ]. One exception is a study that correlated acute findings on CT perfusion scans at the time of TBI with disability (although not employment status) at six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/24\">",
"     24",
"    </a>",
"    ]. It remains unclear what role these factors have in producing the clinical symptomatology of PCS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Psychogenic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A psychogenic contribution to PCS is suggested by a number of empiric and clinical observations. The symptom complex of PCS (headache, dizziness, and sleep impairment) is similar to the somatization seen in psychiatric disorders including depression, anxiety, and posttraumatic stress disorder. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=see_link\">",
"     \"Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis\"",
"    </a>",
"    .) In addition, anxiety and depression can produce subjective and objective cognitive deficits that are similar to those seen in PCS and that improve with antidepressant treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of studies suggest that both psychiatric predispositions (poor coping skills, limited social support and negative perceptions) and psychiatric comorbidity (depression, anxiety and panic, acute and post-traumatic stress disorder) are more prevalent in patients with PCS compared with general population controls",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    with head-injured patients who do not develop persistent PCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/5,8,27-34\">",
"     5,8,27-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, studies of the interaction of depression, anxiety, and cognitive performance in mild traumatic brain injury (TBI) are limited. Some investigators did not find a substantial correlation between the level of depressive symptoms and cognitive deficits in patients with mild TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/35\">",
"     35",
"    </a>",
"    ], while others have found a correlation in the response to antidepressant treatment in a subset of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The association of psychiatric disease and PCS is not established. Limitations in methodology, including cross-sectional design and patient and control group selection bias, preclude firm conclusions. Also, such an association could have several explanations. Patients with premorbid psychiatric disease may be more likely to suffer head injury as a result of more prevalent alcoholism, motor or physical impairments resulting from their disease or medications, and other reasons. Alternatively, patients with psychiatric disease may be more prone to develop PCS after head injury. Finally, head injury may cause or precipitate psychiatric disease in susceptible individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The very low, even absent, rates of postconcussion symptomatology, in some countries and in children, that are sometimes reported suggests a prominent role for sociocultural factors in the pathogenesis of PCS, perhaps because of misattribution or litigation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Misattribution &mdash; Because patients expect PCS symptomatology after TBI, they and their physicians may mistakenly attribute their complaints to the head injury, when they are actually unrelated. In support of this theory, a number of studies have compared patients with mild TBI to non-head-injured controls finding a high prevalence of the same symptoms in both groups, indicating a high base rate of symptoms in the general population [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]. At the same time, surveys of individuals with no history of head injury find that most people identify symptoms of PCS as expected after head injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Litigation &mdash; The idea that pending compensation claims contribute to the presence and duration of PCS symptomatology dates back to original reports in the late nineteenth century. Studies do show a relationship between persistent PCS and potential financial compensation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/42,43\">",
"       42,43",
"      </a>",
"      ]. The association does not clearly imply causation, however. Some patients with pending litigation improve with or without treatment, and PCS occurs in the absence of litigation. On the other hand, failure of patients to recover after claims are settled does not necessarily invalidate this theory, as a financial settlement may in fact reinforce illness behavior. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Persistent postconcussion syndrome'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Chronic pain &mdash; Patients with chronic pain have symptoms of PCS at a rate similar to a comparison group of patients after head injury [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/44,45\">",
"       44,45",
"      </a>",
"      ]. Similar patterns of cognitive deficits may be seen in patients with chronic pain and PCS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/26\">",
"       26",
"      </a>",
"      ]. It is not clear whether this reflects a shared prevalence of psychiatric disorders among sufferers of PCS and chronic pain syndromes, suggests that PCS is a manifestation of a chronic pain syndrome, or reflects the ubiquitous nature of these symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complaints in postconcussion syndrome (PCS) are headaches, dizziness, fatigue, irritability, anxiety, insomnia, loss of concentration and memory, and noise sensitivity. The relative preponderance of these symptoms varies from study to study depending on the clinical setting, the time since injury, and other variables. As an example, among 118 patients who volunteered for a mild traumatic brain injury (TBI) treatment study, at one month following the injury headaches were reported in 78 percent, dizziness in 59 percent, fatigue in 91 percent, irritability in 62 percent, anxiety in 63 percent, sleep disturbance in 70 percent, forgetfulness in 73 percent, and noise sensitivity in 46 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/46\">",
"     46",
"    </a>",
"    ]. Among patients referred to a headache clinic, about half had cognitive complaints, and a quarter had psychological complaints; 17 percent had an isolated complaint of headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Headaches are variably estimated as occurring in 25 to 78 percent of persons following mild TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Paradoxically, headache prevalence, duration, and severity is greater in those with mild head injury compared with those with more severe trauma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. A significant number of patients have pre-existing headaches, but studies conflict as to whether this is a risk factor for post-traumatic headaches [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    According to the International Headache Society (IHS) criteria, the onset of the headache should be within seven days after the injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/53\">",
"     53",
"    </a>",
"    ]. The seven-day onset is arbitrary, particularly since the etiology of post-traumatic migraine is not understood. Three months seems a more reasonable latency for onset than does seven days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most post-traumatic headaches can be classified by IHS type similarly to nontraumatic headaches. Migraine and tension headaches predominate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/2,47,49,54\">",
"     2,47,49,54",
"    </a>",
"    ]. In most series, tension-type headaches are most frequent (75 to 77 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/2,47\">",
"     2,47",
"    </a>",
"    ]; however, among US soldiers with post-traumatic headaches mainly associated with blast trauma, most were of the migraine-type [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/54\">",
"     54",
"    </a>",
"    ] Many patients (27 to 75 percent) have more than one type of headache [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/47,49\">",
"     47,49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Tension type",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tension type headaches may occur daily, either as a constant or intermittent pain with variable duration. Their distribution may be generalized, nuchal-occipital, bifrontal, bitemporal, headband or cap-like, and they are characteristically described as a pressure, tightness, or dull aching. Analgesic overuse complicated 42 percent of post-traumatic headaches in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link&amp;anchor=H2#H2\">",
"     \"Headache syndromes other than migraine\", section on 'Tension type headache'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Migraine headache is typically lateralized, pounding or throbbing in nature, with associated photophobia and nausea. It occurs with and without visual aura. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=see_link\">",
"     \"Pathophysiology, clinical manifestations, and diagnosis of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recurring attacks of migraine with and without aura can result from mild head injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/55\">",
"     55",
"    </a>",
"    ]. Impact can also cause acute migraine episodes, often in adolescents with a family history of migraine. Originally termed \"footballer's migraine\" to describe young men playing soccer who had multiple migraine with aura attacks triggered only by impact, similar attacks can be triggered by mild head injury in any sport [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Other post-traumatic headache syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many other headache syndromes may occur in association with mild TBI. These more specific injuries are not necessarily considered typical features of PCS and can occur in isolation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Temporomandibular joint injury can be caused either by direct trauma or jarring associated with the head injury. Patients may complain of jaw pain and ipsilateral hemicranial or frontotemporal aching or pressure headaches. (See",
"      <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=see_link\">",
"       \"Temporomandibular disorders in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Occipital neuralgia may result from direct nerve injury or entrapment from contiguous musculoskeletal injury. The aching, pressure, stabbing, or throbbing pain may be in a nuchal-occipital",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      parietal, temporal, frontal, or periorbital or retroorbital distribution. Digital pressure over the greater occipital nerve at the mid superior nuchal line (halfway between the posterior mastoid and the occipital protuberance) may reproduce the headache. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=see_link&amp;anchor=H8#H8\">",
"       \"Overview of craniofacial pain\", section on 'Occipital neuralgia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Trigeminal nerve injury produces shooting, tingling, aching, or burning pain that may be paroxysmal or constant. Isolated injuries to the supraorbital or infraorbital branches can accompany minor head injury. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=see_link&amp;anchor=H19#H19\">",
"       \"Overview of craniofacial pain\", section on 'Posttraumatic and postoperative pain'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dysesthesias over scalp lacerations occur frequently. In the presence or absence of a laceration, an aching, soreness, tingling, or shooting pain over the site of the original trauma can develop. The symptoms may persist for weeks or months but rarely for more than one year.",
"     </li>",
"     <li>",
"      Low CSF pressure may result from trauma causing a CSF leak through a dural root sleeve tear or a cribiform plate fracture. This may produce a headache syndrome with prominent positional exacerbation (headache absent when supine and severe when upright) as is seen in post-lumbar puncture headache. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20198?source=see_link\">",
"       \"Post-lumbar puncture headache\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cortical contusions can cause a headache, especially if there is associated subarachnoid hemorrhage.",
"     </li>",
"     <li>",
"      Traumatic dissection of the carotid and vertebral arteries can cause persistent throbbing headache. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=see_link&amp;anchor=H16#H16\">",
"       \"Overview of craniofacial pain\", section on 'Carotidynia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other headache syndromes attributed to trauma in case reports include cluster headaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/57\">",
"       57",
"      </a>",
"      ]; hemicrania continua [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/58\">",
"       58",
"      </a>",
"      ]; short-lasting unilateral neuralgiform headache attacks with conjunctival injection, tearing, sweating, and rhinorrhea (SUNCT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/59\">",
"       59",
"      </a>",
"      ]; short-lasting unilateral headache with cranial autonomic symptoms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/60\">",
"       60",
"      </a>",
"      ], and paroxysmal hemicrania [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/61\">",
"       61",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=see_link\">",
"       \"Cluster headache: Epidemiology, clinical features, and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=see_link\">",
"       \"SUNCT and SUNA headache syndromes: Clinical features and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=see_link\">",
"       \"Paroxysmal hemicrania: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dizziness",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-half of patients report dizziness after mild head injury. While some patients with PCS have nonspecific dizziness (lightheadedness), others report true vertigo that may be due to benign paroxysmal positional vertigo or to a labyrinthine concussion. A number of studies suggest that complaints of dizziness at the time of injury and afterward identify patients at risk of prolonged recovery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/62-65\">",
"     62-65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link&amp;anchor=H20#H20\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Post-traumatic vertigo'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=see_link\">",
"     \"Approach to the patient with dizziness\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=see_link\">",
"     \"Benign paroxysmal positional vertigo\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Psychological and cognitive symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 50 percent of patients report personality change, irritability, anxiety, and depression after mild TBI. They may find themselves intolerant of noise, emotional excitement and crowds, and more susceptible to the effects of alcohol. Family members may report that the patient seems more abrupt, argumentative, stubborn, opinionated, or suspicious.",
"   </p>",
"   <p>",
"    Patients also report impaired memory and concentration; these may be corroborated by objective deficits on neuropsychological testing. In typical cases, these are most prominent immediately after the injury and resolve over the next weeks and months. Fatigue and disruption of sleep patterns, usually insomnia, are also reported.",
"   </p>",
"   <p>",
"    A significant number of patients (15 to 20 percent) will develop symptoms meeting criteria for psychiatric disease. These include acute stress and post-traumatic stress disorder as well as anxiety, panic disorder, and depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/5,19,30,66\">",
"     5,19,30,66",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The judicious use of testing needs to be individualized for each patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/67\">",
"     67",
"    </a>",
"    ]. Referrals to an ophthalmologist or otorhinolaryngologist should be made for patients with persistent complaints of visual symptoms or vertigo. Psychiatric evaluation should be considered for patients with prominent psychiatric symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neuropsychological testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuropsychological testing is not helpful in most patients with postconcussion symptoms. Nevertheless, when performed by a knowledgeable and experienced psychologist, neuropsychologic evaluation can be helpful for evaluating selected patients with prominent cognitive or psychologic complaints, providing reassurance as to their mild nature and limited extent.",
"   </p>",
"   <p>",
"    Follow-up studies of unselected patients after mild traumatic brain injury (TBI) demonstrate small measurable deficits on neuropsychological testing. Cognitive domains that appear particularly vulnerable to the effects of head injury include attention, working memory, processing speed, and reaction time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/47\">",
"     47",
"    </a>",
"    ]. The deficits are generally mild; gross deficits of intelligence and memory are not associated with mild TBI. Abnormalities are most prominent in the first week after TBI and disappear over time. At three months, patients with mild TBI as a group perform similarly to control subjects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/68,69\">",
"     68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observed cognitive deficits are not specific to mild TBI; similar patterns of abnormalities are seen in patients with psychological illness, pain syndromes, and those taking medications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/11,25,70\">",
"     11,25,70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neuropsychological testing may demonstrate findings inconsistent with PCS that can be helpful to the physician in pursuing alternative diagnoses. The referring physician should be aware that neuropsychological testing is not well standardized, and findings are easily subject to misinterpretation and overinterpretation for a variety of reasons, especially in medico-legal cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/67,71\">",
"     67,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients evaluated for mild TBI will have undergone a CT scan or MRI as part of their acute evaluation. About 10 percent of CT scans in mild TBI are abnormal showing mild subarachnoid hemorrhage, subdural hemorrhage, or contusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/72\">",
"     72",
"    </a>",
"    ]. MRI is more sensitive than CT scan showing abnormalities in about 30 percent of patients with normal CT scans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=see_link&amp;anchor=H12#H12\">",
"     \"Concussion and mild traumatic brain injury\", section on 'Neuroimaging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient with PCS who have not had an MRI and have disabling complaints should have a brain MRI to exclude more serious pathology that would either identify a worse prognosis or an alternative cause for their symptoms.",
"   </p>",
"   <p>",
"    Other advanced neuroimaging techniques, including functional MRI, magnetic resonance spectroscopy, and diffusion tensor imaging, are under investigation in the evaluation of patients with TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/75,76\">",
"     75,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of postconcussion syndrome (PCS) is individualized to the patient's particular complaints. Simple reassurance is often the major treatment, since most patients will improve within three months. A trial of six days of bedrest in 107 patients presenting to the emergency department after a mild head injury reduced complaints of dizziness in the first week after injury but did not alter the severity of post-traumatic complaints at three or six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the absence of specific treatments for the prevention or treatment of PCS, most clinicians adopt a symptomatic approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Headaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information about treating headache syndromes specifically in the post-traumatic setting is limited to case series:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       Amitriptyline",
"      </a>",
"      has been widely used for post-traumatic tension type headaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/78\">",
"       78",
"      </a>",
"      ] as well as for the nonspecific symptoms such as irritability, dizziness, depression, fatigue, and insomnia.",
"     </li>",
"     <li>",
"      An inpatient program of repetitive intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/13/15574?source=see_link\">",
"       dihydroergotamine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      may provide relief of refractory chronic post-traumatic headaches [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/79\">",
"       79",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Greater occipital neuralgia frequently responds to greater occipital nerve block [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/80\">",
"       80",
"      </a>",
"      ] with a local anesthetic, which can also be combined with an injectable corticosteroid.",
"     </li>",
"     <li>",
"      A trial of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"       propranolol",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/30/27112?source=see_link\">",
"       amitriptyline",
"      </a>",
"      alone or in combination produced a 70 percent response rate in 21 of 30 adequately treated patients with post-traumatic migraine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Analgesia overuse was a common contributor to post-traumatic headache in 19 to 42 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/2,47\">",
"       2,47",
"      </a>",
"      ]. These patients responded to analgesic withdrawal as favorably as patients whose headaches were not post-traumatic.",
"     </li>",
"     <li>",
"      Patients with post-traumatic paroxysmal hemicrania and hemicrania continua have responded to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/50/36649?source=see_link\">",
"       indomethacin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/58,61\">",
"       58,61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the absence of controlled studies specific to PCS, these data suggest that post-traumatic headaches will likely respond to those treatments used for migraine and tension headache that are used in other settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/47\">",
"     47",
"    </a>",
"    ]. Clinicians caring for these patients note that delayed recovery from post-traumatic headaches may be due to inadequately aggressive treatment, analgesia overuse, or comorbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/48\">",
"     48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=see_link\">",
"     \"Headache syndromes other than migraine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=see_link\">",
"     \"Acute treatment of migraine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=see_link\">",
"     \"Preventive treatment of migraine in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Psychologic and cognitive complaints",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current evidence does not provide information for treatment of these complaints that are specific to the post-traumatic setting.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/30/10726?source=see_link\">",
"     Donepezil",
"    </a>",
"    has had positive results in preliminary studies in patients with more severe traumatic brain injury (TBI) but has not been studied extensively in PCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Six patients with chronic symptoms after mild head injury reported subjective cognitive improvement in an open-label study of donepezil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/84\">",
"     84",
"    </a>",
"    ]. A small, randomized trial of CDP-choline in 14 men with mild to moderate TBI was associated with improvement in PCS symptoms and some, but not all, neuropsychological test results after one month [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of cognitive retraining for cognitive difficulties after mild head injury is controversial. Because cognitive rehabilitation can be quite costly, prospective studies are needed demonstrating efficacy before widespread application can be recommended. Simple techniques, such as training in the use of a notebook and visual imagery may be helpful for patients who have memory impairments.",
"   </p>",
"   <p>",
"    When the psychologic symptoms are particularly prominent, supportive psychotherapy and the use of antidepressant and anxiolytic medications may be helpful. Again, there are only limited data supporting a treatment approach specific to the PCS setting. Treatment with oxiracetam was described as being helpful for postconcussion symptoms in a single report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/86\">",
"     86",
"    </a>",
"    ]. In one study, 15 patients with mild TBI who also met criteria for major depression were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    for eight weeks, achieving substantial remission in depressive symptoms as well as improvement in cognitive measures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/27\">",
"     27",
"    </a>",
"    ]. An open-label study in 20 patients with depression after TBI showed symptomatic improvements with treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/56/13193?source=see_link\">",
"     citalopram",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/87\">",
"     87",
"    </a>",
"    ]. Two small randomized trials have found that cognitive behavioral therapy improved symptoms of anxiety",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    depression in patients who had had a mild TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most important roles for the physician is education of the patient and family members, other physicians, and, as appropriate, employers, attorneys, and representatives of insurance companies. Many patients are reassured to discover that their symptoms are not unique or crazy but are instead part of a well-described syndrome. Disbelieving family members may become more supportive with education.",
"   </p>",
"   <p>",
"    Early education and support may also affect the course of PCS. This was illustrated in a follow-up study of 73 patients with mild TBI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/90\">",
"     90",
"    </a>",
"    ]. Those who reported a belief at the time of injury that long-lasting negative effects were a probable outcome were more likely to have enduring symptoms at three months than those who did not endorse this belief [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/90\">",
"     90",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of controlled studies have examined the role of education and reassurance in ameliorating PCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/91-97\">",
"     91-97",
"    </a>",
"    ]. Interventions have included a single follow-up session with reassurance and education; provision of an information booklet; scheduled follow-up phone calls scripted to address education, reassurance, and reactivation; structured behavioral cognitive interventions; and follow-up sessions with multidisciplinary evaluations. Most, but not all, studies suggest that early intervention with information and reassurance may provide a benefit to patients with mild TBI in reducing the severity of PCS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/89,98,99\">",
"     89,98,99",
"    </a>",
"    ].The more intensive multidisciplinary evaluations do not clearly add substantively to the simpler interventions of education and reassurance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms and disability attributed to postconcussion syndrome (PCS) are greatest within the first 7 to 10 days for the majority of patients. At one month, symptoms are improved and in many cases resolved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/100\">",
"     100",
"    </a>",
"    ]. The vast majority of patients have largely recovered by three months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/101\">",
"     101",
"    </a>",
"    ]. A minority (10 to 15 percent) have symptoms that persist one year or longer. Because of biased reporting, it is possible that this number is inflated, and the overall prevalence is much lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Persistent postconcussion syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with disabling symptoms that persist after several months or a year may be more disabled than they were immediately after the injury. While the entire symptom complex persists in most cases, emotional symptoms seem particularly prominent. Studies in general have been unable to define risk factors for this subset; premorbid psychosocial factors or psychiatric disease have not consistently been shown to define those patients at risk of a protracted course.",
"   </p>",
"   <p>",
"    A comprehensive review of studies examining the prognosis for recovery after mild traumatic brain injury (TBI) made the following points [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/102\">",
"     102",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Litigation or compensation issues are a strong consistent risk factor for persistent symptoms and disability after mild TBI.",
"     </li>",
"     <li>",
"      Repeated concussions may lead to more severe and more protracted cognitive deficits, but the cross-sectional design of the studies preclude a causal inference.",
"     </li>",
"     <li>",
"      Female gender is an inconsistent risk factor for persistent symptoms.",
"     </li>",
"     <li>",
"      Patients with a Glasgow Coma Scale (GCS) score of 13 have higher rates of disability than those with a GCS of 15, but this may be attributable to other injuries. Patients with complicated TBI (intracranial hematoma or depressed skull fracture) may also be at risk for more persistent symptoms.",
"     </li>",
"     <li>",
"      Limited reports suggest that premorbid physical limitations, prior head injury or other neurologic disease, psychiatric disease, life stressors, student status, TBI after motor vehicle accident, and older age may be risk factors for persistent symptoms.",
"     </li>",
"     <li>",
"      Some patients with persistent disability may be malingering. However, studies of this phenomenon are limited by poorly validated measures of malingering, the cross-sectional nature of the studies, and a significant delay between the head injury and evaluation.",
"      <br/>",
"      <br/>",
"      Potential indicators of malingering include premorbid antisocial and borderline personality traits, poor work record, and prior claims for injury; uncooperative, evasive, or suspicious behavior; inconsistencies in neuropsychological test performance; or engaging in activities inconsistent with reported deficits, having significant financial stressors, and lack of reasonable follow-through on treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/43,103\">",
"       43,103",
"      </a>",
"      ]. Caution in diagnosing malingering is advised; comprehensive multidisciplinary evaluations to detect malingering are incompletely validated, and symptom exaggeration is known to occur in biologic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33929/abstract/104\">",
"       104",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7512?source=see_link\">",
"       \"Factitious disorder and Munchausen syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22722?source=see_link\">",
"       \"Patient information: Concussion (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=see_link\">",
"       \"Patient information: Closed head injury (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/29/20945?source=see_link\">",
"       \"Patient information: Postconcussion syndrome (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postconcussion syndrome (PCS) refers to a common constellation of symptoms reported by patients after mild traumatic brain injury (TBI).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common complaints include headache, dizziness, cognitive impairment, and psychological symptoms. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women and older patients appear to be more susceptible to the development of postconcussion symptoms. The severity of the brain injury does not clearly correlate with the risk of developing PCS or the prognosis for recovery. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Theories of the pathogenesis of the syndrome include both structural and biochemical brain injury as well as psychogenic mechanisms. These may play different etiologic roles at different times in the course of the disorder. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who did not have MRI as part of their acute injury evaluation, a brain MRI should be performed if there are persistent and disabling complaints to exclude other causes; reassurance should also be provided. Because of the nonspecific nature of the results, neuropsychological testing should be reserved for selected patients. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnostic testing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the absence of a defined specific treatment for this disorder, symptomatic treatment is suggested, which may include migraine medications, analgesics, psychological counseling,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      psychotropic medications as dictated by patient complaints and disability (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Education and reassurance shortly after the injury are also suggested (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients recover quickly, within several weeks. A minority have prolonged disability. Litigation and comorbidity may play a role in these patients. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/1\">",
"      Bazarian JJ, Wong T, Harris M, et al. Epidemiology and predictors of post-concussive syndrome after minor head injury in an emergency population. Brain Inj 1999; 13:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/2\">",
"      Haas DC. Chronic post-traumatic headaches classified and compared with natural headaches. Cephalalgia 1996; 16:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/3\">",
"      Evans RW. Persistent post-traumatic headache, postconcussion syndrome, and whiplash injuries: the evidence for a non-traumatic basis with an historical review. Headache 2010; 50:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/4\">",
"      Practice parameter: the management of concussion in sports (summary statement). Report of the Quality Standards Subcommittee. Neurology 1997; 48:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/5\">",
"      McCauley SR, Boake C, Pedroza C, et al. Postconcussional disorder: Are the DSM-IV criteria an improvement over the ICD-10? J Nerv Ment Dis 2005; 193:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/6\">",
"      de Kruijk JR, Leffers P, Meerhoff S, et al. Effectiveness of bed rest after mild traumatic brain injury: a randomised trial of no versus six days of bed rest. J Neurol Neurosurg Psychiatry 2002; 73:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/7\">",
"      Hughes DG, Jackson A, Mason DL, et al. Abnormalities on magnetic resonance imaging seen acutely following mild traumatic brain injury: correlation with neuropsychological tests and delayed recovery. Neuroradiology 2004; 46:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/8\">",
"      McCauley SR, Boake C, Levin HS, et al. Postconcussional disorder following mild to moderate traumatic brain injury: anxiety, depression, and social support as risk factors and comorbidities. J Clin Exp Neuropsychol 2001; 23:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/9\">",
"      Bazarian JJ, Atabaki S. Predicting postconcussion syndrome after minor traumatic brain injury. Acad Emerg Med 2001; 8:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/10\">",
"      Fenton G, McClelland R, Montgomery A, et al. The postconcussional syndrome: social antecedents and psychological sequelae. Br J Psychiatry 1993; 162:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/11\">",
"      Iverson GL. Outcome from mild traumatic brain injury. Curr Opin Psychiatry 2005; 18:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/12\">",
"      Lishman WA. Physiogenesis and psychogenesis in the 'post-concussional syndrome'. Br J Psychiatry 1988; 153:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/13\">",
"      Kant R, Smith-Seemiller L, Isaac G, Duffy J. Tc-HMPAO SPECT in persistent post-concussion syndrome after mild head injury: comparison with MRI/CT. Brain Inj 1997; 11:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/14\">",
"      Korn A, Golan H, Melamed I, et al. Focal cortical dysfunction and blood-brain barrier disruption in patients with Postconcussion syndrome. J Clin Neurophysiol 2005; 22:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/15\">",
"      Umile EM, Sandel ME, Alavi A, et al. Dynamic imaging in mild traumatic brain injury: support for the theory of medial temporal vulnerability. Arch Phys Med Rehabil 2002; 83:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/16\">",
"      Chen SH, Kareken DA, Fastenau PS, et al. A study of persistent post-concussion symptoms in mild head trauma using positron emission tomography. J Neurol Neurosurg Psychiatry 2003; 74:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/17\">",
"      Bogduk N. The neck and headaches. Neurol Clin 2004; 22:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/18\">",
"      Chen JK, Johnston KM, Collie A, et al. A validation of the post concussion symptom scale in the assessment of complex concussion using cognitive testing and functional MRI. J Neurol Neurosurg Psychiatry 2007; 78:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/19\">",
"      Chen JK, Johnston KM, Petrides M, Ptito A. Neural substrates of symptoms of depression following concussion in male athletes with persisting postconcussion symptoms. Arch Gen Psychiatry 2008; 65:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/20\">",
"      Niogi SN, Mukherjee P, Ghajar J, et al. Structural dissociation of attentional control and memory in adults with and without mild traumatic brain injury. Brain 2008; 131:3209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/21\">",
"      Shumskaya E, Andriessen TM, Norris DG, Vos PE. Abnormal whole-brain functional networks in homogeneous acute mild traumatic brain injury. Neurology 2012; 79:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/22\">",
"      Levin HS, Williams DH, Eisenberg HM, et al. Serial MRI and neurobehavioural findings after mild to moderate closed head injury. J Neurol Neurosurg Psychiatry 1992; 55:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/23\">",
"      Wilde EA, McCauley SR, Hunter JV, et al. Diffusion tensor imaging of acute mild traumatic brain injury in adolescents. Neurology 2008; 70:948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/24\">",
"      Metting Z, R&ouml;diger LA, Stewart RE, et al. Perfusion computed tomography in the acute phase of mild head injury: regional dysfunction and prognostic value. Ann Neurol 2009; 66:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/25\">",
"      Brand N, Jolles J. Information processing in depression and anxiety. Psychol Med 1987; 17:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/26\">",
"      Nicholson K, Martelli MF, Zasler ND. Does pain confound interpretation of neuropsychological test results? NeuroRehabilitation 2001; 16:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/27\">",
"      Fann JR, Uomoto JM, Katon WJ. Cognitive improvement with treatment of depression following mild traumatic brain injury. Psychosomatics 2001; 42:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/28\">",
"      Hou R, Moss-Morris R, Peveler R, et al. When a minor head injury results in enduring symptoms: a prospective investigation of risk factors for postconcussional syndrome after mild traumatic brain injury. J Neurol Neurosurg Psychiatry 2012; 83:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/29\">",
"      Tatrow K, Blanchard EB, Hickling EJ, Silverman DJ. Posttraumatic headache: biopsychosocial comparisons with multiple control groups. Headache 2003; 43:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/30\">",
"      Deb S, Lyons I, Koutzoukis C, et al. Rate of psychiatric illness 1 year after traumatic brain injury. Am J Psychiatry 1999; 156:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/31\">",
"      Borgaro SR, Prigatano GP, Kwasnica C, Rexer JL. Cognitive and affective sequelae in complicated and uncomplicated mild traumatic brain injury. Brain Inj 2003; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/32\">",
"      Hoge CW, McGurk D, Thomas JL, et al. Mild traumatic brain injury in U.S. Soldiers returning from Iraq. N Engl J Med 2008; 358:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/33\">",
"      Schneiderman AI, Braver ER, Kang HK. Understanding sequelae of injury mechanisms and mild traumatic brain injury incurred during the conflicts in Iraq and Afghanistan: persistent postconcussive symptoms and posttraumatic stress disorder. Am J Epidemiol 2008; 167:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/34\">",
"      van Veldhoven LM, Sander AM, Struchen MA, et al. Predictive ability of preinjury stressful life events and post-traumatic stress symptoms for outcomes following mild traumatic brain injury: analysis in a prospective emergency room sample. J Neurol Neurosurg Psychiatry 2011; 82:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/35\">",
"      Sherman EM, Strauss E, Slick DJ, Spellacy F. Effect of depression on neuropsychological functioning in head injury: measurable but minimal. Brain Inj 2000; 14:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/36\">",
"      Ferrari R, Obelieniene D, Russell AS, et al. Symptom expectation after minor head injury. A comparative study between Canada and Lithuania. Clin Neurol Neurosurg 2001; 103:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/37\">",
"      Mickeviciene D, Schrader H, Obelieniene D, et al. A controlled prospective inception cohort study on the post-concussion syndrome outside the medicolegal context. Eur J Neurol 2004; 11:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/38\">",
"      Gouvier WD, Uddo-Crane M, Brown LM. Base rates of post-concussional symptoms. Arch Clin Neuropsychol 1988; 3:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/39\">",
"      Gunstad J, Suhr JA. Cognitive factors in Postconcussion Syndrome symptom report. Arch Clin Neuropsychol 2004; 19:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/40\">",
"      Meares S, Shores EA, Taylor AJ, et al. Mild traumatic brain injury does not predict acute postconcussion syndrome. J Neurol Neurosurg Psychiatry 2008; 79:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/41\">",
"      Mittenberg W, DiGiulio DV, Perrin S, Bass AE. Symptoms following mild head injury: expectation as aetiology. J Neurol Neurosurg Psychiatry 1992; 55:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/42\">",
"      Ponsford J, Willmott C, Rothwell A, et al. Factors influencing outcome following mild traumatic brain injury in adults. J Int Neuropsychol Soc 2000; 6:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/43\">",
"      Binder LM, Rohling ML. Money matters: a meta-analytic review of the effects of financial incentives on recovery after closed-head injury. Am J Psychiatry 1996; 153:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/44\">",
"      Smith-Seemiller L, Fow NR, Kant R, Franzen MD. Presence of post-concussion syndrome symptoms in patients with chronic pain vs mild traumatic brain injury. Brain Inj 2003; 17:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/45\">",
"      Iverson GL, McCracken LM. 'Postconcussive' symptoms in persons with chronic pain. Brain Inj 1997; 11:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/46\">",
"      Paniak C, Reynolds S, Phillips K, et al. Patient complaints within 1 month of mild traumatic brain injury: a controlled study. Arch Clin Neuropsychol 2002; 17:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/47\">",
"      Baandrup L, Jensen R. Chronic post-traumatic headache--a clinical analysis in relation to the International Headache Classification 2nd Edition. Cephalalgia 2005; 25:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/48\">",
"      Lane JC, Arciniegas DB. Post-traumatic Headache. Curr Treat Options Neurol 2002; 4:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/49\">",
"      Couch JR, Bearss C. Chronic daily headache in the posttrauma syndrome: relation to extent of head injury. Headache 2001; 41:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/50\">",
"      Stovner LJ, Schrader H, Mickeviciene D, et al. Headache after concussion. Eur J Neurol 2009; 16:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/51\">",
"      Jensen OK, Nielsen FF. The influence of sex and pre-traumatic headache on the incidence and severity of headache after head injury. Cephalalgia 1990; 10:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/52\">",
"      Russell, MB, Olesen, J. Migraine associated with head trauma. Eur J Neurol 1996; 3:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/53\">",
"      Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004; 24 Suppl 1:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/54\">",
"      Vargas BB. Posttraumatic headache in combat soldiers and civilians: what factors influence the expression of tension-type versus migraine headache? Curr Pain Headache Rep 2009; 13:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/55\">",
"      Solomon S. John Graham Senior Clinicians Award Lecture. Posttraumatic migraine. Headache 1998; 38:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/56\">",
"      Matthews WB. Footballer's migraine. Br Med J 1972; 2:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/57\">",
"      Finkel AG. Epidemiology of cluster headache. Curr Pain Headache Rep 2003; 7:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/58\">",
"      Lay CL, Newman LC. Posttraumatic hemicrania continua. Headache 1999; 39:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/59\">",
"      Putzki N, Nirkko A, Diener HC. Trigeminal autonomic cephalalgias: a case of post-traumatic SUNCT syndrome? Cephalalgia 2005; 25:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/60\">",
"      Jacob S, Saha A, Rajabally Y. Post-traumatic short-lasting unilateral headache with cranial autonomic symptoms (SUNA). Cephalalgia 2008; 28:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/61\">",
"      Matharu MJ, Goadsby PJ. Post-traumatic chronic paroxysmal hemicrania (CPH) with aura. Neurology 2001; 56:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/62\">",
"      Lau BC, Kontos AP, Collins MW, et al. Which on-field signs/symptoms predict protracted recovery from sport-related concussion among high school football players? Am J Sports Med 2011; 39:2311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/63\">",
"      Chamelian L, Feinstein A. Outcome after mild to moderate traumatic brain injury: the role of dizziness. Arch Phys Med Rehabil 2004; 85:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/64\">",
"      De Kruijk JR, Leffers P, Menheere PP, et al. Prediction of post-traumatic complaints after mild traumatic brain injury: early symptoms and biochemical markers. J Neurol Neurosurg Psychiatry 2002; 73:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/65\">",
"      Yang CC, Tu YK, Hua MS, Huang SJ. The association between the postconcussion symptoms and clinical outcomes for patients with mild traumatic brain injury. J Trauma 2007; 62:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/66\">",
"      Harvey AG, Bryant RA. Predictors of acute stress following mild traumatic brain injury. Brain Inj 1998; 12:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/67\">",
"      Rees PM. Contemporary issues in mild traumatic brain injury. Arch Phys Med Rehabil 2003; 84:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/68\">",
"      Belanger HG, Curtiss G, Demery JA, et al. Factors moderating neuropsychological outcomes following mild traumatic brain injury: a meta-analysis. J Int Neuropsychol Soc 2005; 11:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/69\">",
"      Schretlen DJ, Shapiro AM. A quantitative review of the effects of traumatic brain injury on cognitive functioning. Int Rev Psychiatry 2003; 15:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/70\">",
"      Meador KJ. Cognitive side effects of medications. Neurol Clin 1998; 16:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/71\">",
"      McCaffrey, RJ, Williams, AD, Fisher, JM, Laing, LC. Forensic issues in mild head injury. J Head Trauma Rehabil 1993; 8:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/72\">",
"      Borg J, Holm L, Cassidy JD, et al. Diagnostic procedures in mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med 2004; :61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/73\">",
"      Hesselink JR, Dowd CF, Healy ME, et al. MR imaging of brain contusions: a comparative study with CT. AJR Am J Roentgenol 1988; 150:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/74\">",
"      Mittl RL, Grossman RI, Hiehle JF, et al. Prevalence of MR evidence of diffuse axonal injury in patients with mild head injury and normal head CT findings. AJNR Am J Neuroradiol 1994; 15:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/75\">",
"      Metting Z, R&ouml;diger LA, De Keyser J, van der Naalt J. Structural and functional neuroimaging in mild-to-moderate head injury. Lancet Neurol 2007; 6:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/76\">",
"      MacDonald CL, Schwarze N, Vaishnavi SN, et al. Verbal memory deficit following traumatic brain injury: assessment using advanced MRI methods. Neurology 2008; 71:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/77\">",
"      Evans RW, Evans RI, Sharp MJ. The physician survey on the post-concussion and whiplash syndromes. Headache 1994; 34:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/78\">",
"      Tyler GS, McNeely HE, Dick ML. Treatment of post-traumatic headache with amitriptyline. Headache 1980; 20:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/79\">",
"      Young, WB, Hopkins, MM, Janyszek, B, Primavera, JP. Repetitive intravenous DHE in the treatment of refractory posttraumatic headache. Headache 1994; 34:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/80\">",
"      Hecht JS. Occipital nerve blocks in postconcussive headaches: a retrospective review and report of ten patients. J Head Trauma Rehabil 2004; 19:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/81\">",
"      Weiss HD, Stern BJ, Goldberg J. Post-traumatic migraine: chronic migraine precipitated by minor head or neck trauma. Headache 1991; 31:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/82\">",
"      Zhang L, Plotkin RC, Wang G, et al. Cholinergic augmentation with donepezil enhances recovery in short-term memory and sustained attention after traumatic brain injury. Arch Phys Med Rehabil 2004; 85:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/83\">",
"      Morey CE, Cilo M, Berry J, Cusick C. The effect of Aricept in persons with persistent memory disorder following traumatic brain injury: a pilot study. Brain Inj 2003; 17:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/84\">",
"      Kaye NS, Townsend JB 3rd, Ivins R. An open-label trial of donepezil (aricept) in the treatment of persons with mild traumatic brain injury. J Neuropsychiatry Clin Neurosci 2003; 15:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/85\">",
"      Levin HS. Treatment of postconcussional symptoms with CDP-choline. J Neurol Sci 1991; 103 Suppl:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/86\">",
"      Russello D, Randazzo G, Favetta A, et al. [Oxiracetam treatment of exogenous post-concussion syndrome. Statistical evaluation of results]. Minerva Chir 1990; 45:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/87\">",
"      Perino C, Rago R, Cicolini A, et al. Mood and behavioural disorders following traumatic brain injury: clinical evaluation and pharmacological management. Brain Inj 2001; 15:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/88\">",
"      Tiersky LA, Anselmi V, Johnston MV, et al. A trial of neuropsychologic rehabilitation in mild-spectrum traumatic brain injury. Arch Phys Med Rehabil 2005; 86:1565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/89\">",
"      Al Sayegh A, Sandford D, Carson AJ. Psychological approaches to treatment of postconcussion syndrome: a systematic review. J Neurol Neurosurg Psychiatry 2010; 81:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/90\">",
"      Whittaker R, Kemp S, House A. Illness perceptions and outcome in mild head injury: a longitudinal study. J Neurol Neurosurg Psychiatry 2007; 78:644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/91\">",
"      Gronwall, D. Rehabilitation programs for patients with mild head injury: components, problems. and evaluation. J Head Trauma Rehab 1986; 1:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/92\">",
"      Ponsford J, Willmott C, Rothwell A, et al. Impact of early intervention on outcome following mild head injury in adults. J Neurol Neurosurg Psychiatry 2002; 73:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/93\">",
"      Alves, W, Macciocchi, SN, Barth, JT. Postconcussive symptoms after uncomplicated mild head injury. J Head Trauma Rehabil 1993; 8:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/94\">",
"      Paniak C, Toller-Lobe G, Reynolds S, et al. A randomized trial of two treatments for mild traumatic brain injury: 1 year follow-up. Brain Inj 2000; 14:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/95\">",
"      Wade DT, King NS, Wenden FJ, et al. Routine follow up after head injury: a second randomised controlled trial. J Neurol Neurosurg Psychiatry 1998; 65:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/96\">",
"      Mittenberg W, Tremont G, Zielinski RE, et al. Cognitive-behavioral prevention of postconcussion syndrome. Arch Clin Neuropsychol 1996; 11:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/97\">",
"      Bell KR, Hoffman JM, Temkin NR, et al. The effect of telephone counselling on reducing post-traumatic symptoms after mild traumatic brain injury: a randomised trial. J Neurol Neurosurg Psychiatry 2008; 79:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/98\">",
"      Borg J, Holm L, Peloso PM, et al. Non-surgical intervention and cost for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med 2004; :76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/99\">",
"      Mittenberg W, Canyock EM, Condit D, Patton C. Treatment of post-concussion syndrome following mild head injury. J Clin Exp Neuropsychol 2001; 23:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/100\">",
"      Triebel KL, Martin RC, Novack TA, et al. Treatment consent capacity in patients with traumatic brain injury across a range of injury severity. Neurology 2012; 78:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/101\">",
"      Kashluba S, Paniak C, Blake T, et al. A longitudinal, controlled study of patient complaints following treated mild traumatic brain injury. Arch Clin Neuropsychol 2004; 19:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/102\">",
"      Carroll LJ, Cassidy JD, Peloso PM, et al. Prognosis for mild traumatic brain injury: results of the WHO Collaborating Centre Task Force on Mild Traumatic Brain Injury. J Rehabil Med 2004; :84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/103\">",
"      Ruff, RM, Wylie, T, Tennant, W. Malingering and malingering-like aspects of mild closed head injury. J Head Trauma Rehabil 1993; 8:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33929/abstract/104\">",
"      Gould R, Miller BL, Goldberg MA, Benson DF. The validity of hysterical signs and symptoms. J Nerv Ment Dis 1986; 174:593.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4830 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33929=[""].join("\n");
var outline_f33_8_33929=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurobiologic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Psychogenic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Headaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Tension type",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Other post-traumatic headache syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dizziness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Psychological and cognitive symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSTIC TESTING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neuropsychological testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Headaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Psychologic and cognitive complaints",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Persistent postconcussion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/4830\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/4830|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/62/29676\" title=\"table 1\">",
"      Glasgow coma scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/44/21194?source=related_link\">",
"      Acute treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23223?source=related_link\">",
"      Approach to the patient with dizziness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/13/19673?source=related_link\">",
"      Benign paroxysmal positional vertigo",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/63/14327?source=related_link\">",
"      Cluster headache: Epidemiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/59/29626?source=related_link\">",
"      Concussion and mild traumatic brain injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/21/7512?source=related_link\">",
"      Factitious disorder and Munchausen syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3624?source=related_link\">",
"      Headache syndromes other than migraine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/38/12906?source=related_link\">",
"      Minor head trauma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/10/11431?source=related_link\">",
"      Overview of craniofacial pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/60/25545?source=related_link\">",
"      Paroxysmal hemicrania: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/4/26698?source=related_link\">",
"      Pathophysiology, clinical manifestations, and diagnosis of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?8/47/8947?source=related_link\">",
"      Patient information: Closed head injury (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?22/12/22722?source=related_link\">",
"      Patient information: Concussion (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/29/20945?source=related_link\">",
"      Patient information: Postconcussion syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/46/20198?source=related_link\">",
"      Post-lumbar puncture headache",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/62/28648?source=related_link\">",
"      SUNCT and SUNA headache syndromes: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/20/5450?source=related_link\">",
"      Somatization: Epidemiology, pathogenesis, clinical features, medical evaluation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./temporomandibular-disorders-in-adults?source=related_link\">",
"      Temporomandibular disorders in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_8_33930="Therapeutic use of heparin and low molecular weight heparin";
var content_f33_8_33930=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"9\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapeutic use of heparin and low molecular weight heparin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33930/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33930/contributors\">",
"     Karen A Valentine, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33930/contributors\">",
"     Russell D Hull, MBBS, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33930/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33930/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/8/33930/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/8/33930/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/8/33930/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic will review the general principles underlying the therapeutic use and monitoring of unfractionated and low molecular weight (LMW) heparins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Specific uses of these",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparations in the treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prevention of thromboembolic disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in medical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and LMW heparin in patients with acute myocardial infarction or stroke is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=see_link\">",
"     \"Antithrombotic treatment of acute ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     USE OF HEPARIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is an indirect thrombin inhibitor which complexes with antithrombin (AT, formerly known as AT III), converting this circulating cofactor from a slow to a rapid inactivator of thrombin, factor Xa, and to a lesser extent, factors XIIa, XIa, and IXa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. AT has two active functional sites: the reactive center, Arg393-Ser394; and the heparin binding site located at its amino terminus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/4\">",
"     4",
"    </a>",
"    ]. The binding of AT to heparin is mediated by a unique pentasaccharide sequence that is randomly distributed along the heparin chains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,5\">",
"     1,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The binding of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to the heparin binding site on AT produces a conformational change in AT, accelerating the inactivating function of AT 1000- to 4000-fold [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/4,6\">",
"     4,6",
"    </a>",
"    ]. Inactivation of thrombin, but not factor Xa, requires the formation of a ternary complex in which heparin binds to both AT and to a binding site on thrombin (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"mobipreview.htm?35/16/36110\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/7\">",
"     7",
"    </a>",
"    ]. This complex forms only on pentasaccharide-containing chains at least 18 saccharide units long; such long units are present in most chains of unfractionated heparin, are less commonly present in the low molecular weight (LMW) heparins, and are not present in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    . Accordingly, LMW heparins and fondaparinux have less antithrombin activity than does unfractionated heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Less important actions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    include direct binding to platelets and, at high concentrations, binding to heparin cofactor II (AT is heparin cofactor I). Heparin does not cross the placenta, making it safer to use in pregnancy than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=see_link\">",
"     \"Anticoagulation during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PRACTICAL ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Limitations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    has a number of limitations, including a narrow therapeutic window of adequate anticoagulation without bleeding, and a highly variable dose-response relation requiring laboratory monitoring. The variable anticoagulant response is due in part to differences in bioavailability of subcutaneous heparin and to competitive occupation of binding sites by plasma proteins (other than AT and coagulation factors), by proteins secreted by platelets (platelet factor 4), and by endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,10\">",
"     1,10",
"    </a>",
"    ]. Some of these heparin-binding proteins are acute phase reactants, thus reducing the effectiveness of heparin in acutely ill patients.",
"   </p>",
"   <p>",
"    The variable response to treatment with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was illustrated in results of the ExTRACT TIMI 25 study, in which 6055 patients with ST-segment elevation myocardial infarction received unfractionated heparin along with a fibrin-specific thrombolytic agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/11\">",
"     11",
"    </a>",
"    ]. Despite close adherence to recommended heparin dosing according to the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association weight-based nomogram, only 34 percent of initial aPTTs were therapeutic (ie, 1.5 to 2.0 times control), 13 percent were markedly low (&lt;1.25 times control), and 16 percent were markedly high (&ge;2.75 times control). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H8#H8\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'Unfractionated heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another limitation to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is a reduced ability to inactivate thrombin bound to fibrin as well as factor Xa bound to activated platelets within a thrombus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/12\">",
"     12",
"    </a>",
"    ]. As a result, a thrombus may continue to grow during heparin therapy or clotting may be reactivated after heparin has been discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Heparin induced thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombocytopenia following the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (heparin-induced thrombocytopenia, HIT) is a potentially fatal complication that may be associated with thrombosis (HITT). This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Heparin monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticoagulant response to a standard dose of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    varies widely among patients. Further, there is insufficient information in the literature to modify the initial dose according to estimates of the patient's \"wet\" versus \"dry\" weight or rapidly changing weight. This makes it necessary to monitor the response in each patient, using the activated partial thromboplastin time (aPTT) or heparin levels (see below), or the activated clotting time in the case of the high doses of heparin as used in interventional cardiology, and to titrate the dose to the individual patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Such measurements should be made prior to heparin therapy, four to six hours after initiation, and four to six hours after any dosage change. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical use of coagulation tests\", section on 'Activated partial thromboplastin time'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical use of coagulation tests\", section on 'Activated whole blood clotting time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the obese subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link&amp;anchor=H14#H14\">",
"     \"Postoperative management of the critically ill obese patient\", section on 'Anticoagulants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with venous thromboembolism, the critical therapeutic level of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (as measured by the aPTT) to be reached within the first 24 hours is 1.5 times the mean of the control value or the upper limit of the normal aPTT range. This level of anticoagulation generally corresponds to a heparin blood level of 0.2 to 0.4",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    by the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    titration assay and 0.3 to 0.7",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    by an amidolytic antifactor Xa assay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,15-17\">",
"     1,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of achieving this therapeutic range within 24 hours according to the aPTT is discussed separately. Failure to promptly achieve a therapeutic aPTT level in patients with VTE treated with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    has been associated with a statistically significant and clinically important increase in the risk of subsequent recurrent thromboembolism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Unfractionated heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As will be described below in the nomograms for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy, the generally accepted value of the aPTT that should be reached for maintenance heparin therapy is 1.5 to 2.5 times the mean of the control value or the upper limit of the normal aPTT range. There is, however, a wide variability in the aPTT and heparin blood levels with different reagents and even with different batches of the same reagent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. As a result, it is vital for each laboratory to establish the minimal therapeutic level of heparin, as measured by the aPTT, that will provide a heparin blood level of at least 0.2",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    by the protamine titration assay for each batch of thromboplastin reagent being used; this is particularly important when switching to a reagent provided by a different manufacturer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Effect of the change in heparin potency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) products manufactured in the United States after October 8, 2009 will be 10 percent less potent because of the use of a new United States Pharmacopeia (USP) reference standard, which will lessen the potential of contamination and calibrate the new material relative to the international standard issued by the World Health Organization",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm207506.htm\">",
"     FDA Safety Alert",
"    </a>",
"    . However, the USP has also stated that \"Due to the inherently low and extremely variable bioavailability of heparin, finished drug product potencies are generally specified with &plusmn;10 percent of the potency values\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Accordingly, changing to the new",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    unit is not likely to have clinical significance for most applications. However, it may be important when UFH is administered as a bolus intravenous dose and an immediate anticoagulant effect is clinically important, prompting consideration about what initial dose to administer. Monitoring of the effect of therapeutic doses of UFH via the aPTT (or the activated clotting time (ACT) in the case of the high doses of heparin as used in interventional cardiology) will be of critical importance in determining the overall effect, if any, of this change in UFH potency. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Heparin monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Addition of warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    generally is begun concomitantly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with venous thromboembolism. The simultaneous use of the two drugs complicates the assessment of the degree of anticoagulation due to heparin if only the aPTT is monitored. As an example, one study of 24 patients with venous thromboembolism found that the effects of heparin and warfarin on the aPTT were additive, and that the aPTT was prolonged approximately 16 seconds for each 1.0 increase in the international normalized ratio [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/21\">",
"     21",
"    </a>",
"    ]. Heparin levels were subtherapeutic in 10 of 29 cases of a supratherapeutic aPTT in this setting. However, the practical implications of this study are unclear because simultaneously administered heparin and warfarin have been shown to be safe and effective in large randomized trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/22\">",
"     22",
"    </a>",
"    ]. A discussion of how to initiate and transition from heparin to warfarin therapy can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H43#H43\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Initial anticoagulation regimen'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=see_link&amp;anchor=H15#H15\">",
"     \"Anticoagulation in acute pulmonary embolism\", section on 'Warfarin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Prolonged baseline aPTT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of a prolonged baseline aPTT makes this test unreliable for monitoring therapy with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical use of coagulation tests\", section on 'Causes of prolonged aPTT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The cause of the prolonged aPTT should be investigated prior to initiating therapy whenever possible. For example, if the reason is a lupus anticoagulant, then an alternative monitoring system may be employed. However, if the patient has a compromised coagulation system (eg, liver disease, DIC) and prolonged clotting times due to one or more factor deficiencies, then the",
"    <span class=\"nowrap\">",
"     risk/benefit",
"    </span>",
"    assessment and therapeutic goals of anticoagulation need to be individualized.",
"   </p>",
"   <p>",
"    A number of options are available for monitoring UFH therapy in patients with prolonged baseline aPTTs:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitor UFH dosing by using an anti-factor Xa assay or a specific",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      assay. In general, these are not affected by the presence of a lupus anticoagulant or factor deficiency.",
"     </li>",
"     <li>",
"      Alternatively, if the reason for a prolonged baseline aPTT is a lupus anticoagulant, one can employ an aPTT test that is not sensitive to the presence of a lupus anticoagulant. The laboratory should be consulted to determine which of these alternative assays is available. Since aPTT assays vary greatly in their sensitivity to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , if a different aPTT assay is employed it should be calibrated so that the targeted therapeutic range in seconds for UFH corresponds to established ranges for UFH by protamine titration (0.2 to 0.4",
"      <span class=\"nowrap\">",
"       Units/mL)",
"      </span>",
"      or anti-Xa activity (0.3 to 0.7",
"      <span class=\"nowrap\">",
"       Units/mL).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Heparin monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use subcutaneous LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in therapeutic doses rather than UFH. Routine monitoring of LMW heparin is not generally required. However, a LMW heparin-specific anti-factor Xa assay can be used for monitoring if questions concerning dosing arise (eg, pregnancy, obesity, renal insufficiency). Note that the therapeutic range for LMW heparin is different from UFH. As an example, the therapeutic range for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      is generally 0.5 to 1.0 anti-Xa",
"      <span class=\"nowrap\">",
"       Units/mL",
"      </span>",
"      when measured four to six hours following injection. (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Anti-factor Xa testing'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In general, the most practical solution will be to use a LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as an alternative to UFH. Where rapid anti-Xa levels or other heparin assays are available (with rapid turnaround for dose adjustments), the use of UFH with such monitoring would also be acceptable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Platelet count monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients receiving unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH), the 2008 and 2012 ACCP Guidelines suggest that platelet counts be obtained regularly to monitor for the development of thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The frequency and timing of such counts depends upon the clinical situation, and were most clearly outlined in the 2008 version of the Guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/23\">",
"     23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients receiving therapeutic-dose UFH, every other day platelet count monitoring is suggested from day 4 to day 14, or until UFH is stopped, whichever occurs first.",
"     </li>",
"     <li>",
"      For patients receiving prophylactic dose UFH or LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , platelet count monitoring is suggested every two to three days from day 4 to day 14, or until heparin is stopped, whichever occurs first.",
"     </li>",
"     <li>",
"      For patients who have received UFH in the past 100 days and who are starting treatment with UFH or LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , who are therefore at risk of developing accelerated thrombocytopenia, a baseline platelet count should be obtained and repeated within 24 hours. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H8#H8\">",
"       \"Heparin-induced thrombocytopenia\", section on 'Onset and degree of thrombocytopenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For",
"      <span class=\"nowrap\">",
"       medical/obstetric",
"      </span>",
"      patients who are only receiving LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , or medical patients who are receiving only intravascular catheter UFH \"flushes\", in whom the incidence of HIT is expected to be &lt;0.1 percent, routine platelet count monitoring is not suggested.",
"     </li>",
"     <li>",
"      Guidelines for the extremely short use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      in patients with a prior diagnosis of heparin-induced thrombocytopenia are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H44#H44\">",
"       \"Heparin-induced thrombocytopenia\", section on 'Use of heparin after an episode of HIT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Heparin resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenomenon of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    resistance refers to patients requiring unusually large doses of heparin in order to achieve an aPTT in the therapeutic range (eg, &gt;35,000 units of heparin per 24 hours, excluding initial bolus doses). Causes of this phenomenon include increased heparin clearance, increased levels of heparin-binding proteins, elevations of fibrinogen and factor VIII levels, certain medications (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/52/6982?source=see_link\">",
"     aprotinin",
"    </a>",
"    ), and antithrombin deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,25\">",
"     1,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized controlled study evaluated the therapeutic benefit when subjects with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    resistance were randomly assigned to have their heparin dosage adjusted either to achieve an anti-factor Xa activity of 0.35 to 0.67 International",
"    <span class=\"nowrap\">",
"     Units/mL",
"    </span>",
"    or an aPTT in the range of 60 to 80 seconds, both of which were equivalent to a heparin level of 0.2 to 0.4",
"    <span class=\"nowrap\">",
"     Units/mL",
"    </span>",
"    by protamine titration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/26\">",
"     26",
"    </a>",
"    ]. The risks of recurrent VTE and bleeding were similar in the two treatment arms, although the dose of heparin required was significantly lower in those being monitored by their anti-factor Xa activity.",
"   </p>",
"   <p>",
"    Accordingly, it has been suggested that adjustment of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing in patients with heparin resistance should be based upon anti-Xa levels rather than the aPTT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Antithrombin deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients with deficiency of antithrombin (AT,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor I, formerly known as ATIII) are resistant to heparin and require large doses. This is in part due to the action of heparin to further lower AT levels by approximately 30 percent. In addition, the majority of patients with heparin resistance are AT-deficient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Treatment of the AT-deficient subject with AT concentrates results in potentiation of the heparin effect and reduction in total heparin usage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antithrombin concentrate has been used safely and effectively in patients with AT deficiency and acute venous thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. It is recommended in those patients who have unusually severe thrombosis, develop recurrent thrombosis despite adequate anticoagulation, or have difficulty achieving adequate anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=see_link\">",
"     \"Antithrombin (ATIII) deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23752?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of inherited thrombophilia\", section on 'Antithrombin deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The intravenous infusion of 50",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    of AT concentrate will usually raise the plasma AT level to approximately 120 percent in a congenitally deficient individual with a baseline value of 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/32,34-36\">",
"     32,34-36",
"    </a>",
"    ]. Plasma levels should be monitored to ensure that they remain above 80 percent; the administration of 60 percent of the initial dose at 24-hour intervals is recommended to maintain AT levels in the normal range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Use of AT concentrate as adjunctive therapy or as an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with AT deficiency and venous thromboembolism has not been studied in a controlled trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Interference with thrombophilia testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    reduces antithrombin levels and interferes with testing for an inherited deficiency of antithrombin. Testing for a lupus anticoagulant, which requires use of a modification of the aPTT, cannot be performed until heparin is stopped (",
"    <a class=\"graphic graphic_table graphicRef76966 \" href=\"mobipreview.htm?43/22/44396\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=see_link&amp;anchor=H23#H23\">",
"     \"Evaluation of the patient with established venous thrombosis\", section on 'Technical screening issues'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ADMINISTRATION AND EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Audits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy indicate that administration of intravenous heparin is fraught with difficulty and that the clinical practice of using an ad hoc approach to heparin dose-titration frequently results in inadequate therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. As an example, a 1988 audit of physician practices at three university-affiliated hospitals documented that 60 percent of treated patients failed to achieve an adequate aPTT response (ie, at least 1.5 times the control value) during the initial 24 hours of therapy, and that 30 to 40 percent of patients remained subtherapeutic over the next three to four days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/40\">",
"     40",
"    </a>",
"    ]. Several practices were identified that led to inadequate therapy. The common theme was fear of bleeding complications on the part of clinicians. These problems have subsequently been alleviated via the use of protocols for the administration of heparin, some of which are described immediately below. However, despite the presence of such protocols, underdosing, along with failure to achieve an adequate aPTT response during the initial 24 hours, is still a problem, especially in the obese patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Treatment of VTE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Intravenous heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a prescriptive approach or protocol for administering intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy has been evaluated in two studies in patients with venous thromboembolism (VTE):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first trial evaluated patients with proximal venous thrombosis who were given either intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      alone followed by",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , or intravenous heparin and simultaneous warfarin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/44\">",
"       44",
"      </a>",
"      ]. The heparin nomogram used in this study is summarized in the tables (",
"      <a class=\"graphic graphic_table graphicRef66081 \" href=\"mobipreview.htm?43/40/44683\">",
"       table 2",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef72792 \" href=\"mobipreview.htm?21/6/21612\">",
"       table 3",
"      </a>",
"      ). Only 1 percent and 2 percent of the patients were subtherapeutic for more than 24 hours in the heparin group and in the heparin and warfarin group, respectively. Objectively documented recurrent VTE occurred infrequently in both groups (7 percent), a rate similar to that previously reported. These findings demonstrated that subtherapeutic dosing was avoided in most patients and that use of this heparin protocol resulted in effective delivery of heparin therapy in both groups.",
"     </li>",
"     <li>",
"      The second trial compared a weight-based",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      dosing nomogram with a standard-care nomogram (",
"      <a class=\"graphic graphic_table graphicRef58483 \" href=\"mobipreview.htm?41/28/42444\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/45\">",
"       45",
"      </a>",
"      ]. Patients treated with the weight-adjusted heparin nomogram received a starting dose of 80",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      as a bolus and 18",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour as an infusion. Patients on the standard-care nomogram received a bolus of 5000 units followed by 1000",
"      <span class=\"nowrap\">",
"       units/hour",
"      </span>",
"      by infusion. The heparin dose was adjusted to maintain an aPTT of 1.5 to 2.3 times control. A higher percentage of patients in the weight-adjusted group achieved the therapeutic range within 24 hours (89 versus 75 percent). The risk of recurrent VTE was higher in the standard-care group (relative risk 5.0, 95% CI 1.1-22), supporting the previous observation that subtherapeutic heparin during the initial 24 hours is associated with a higher incidence of VTE recurrence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to patients with VTE, this study included patients with unstable angina and arterial thromboembolism, suggesting that the principles applied to a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    nomogram for the treatment of VTE may be generalizable to other clinical conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Subcutaneous UFH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of subcutaneous (SQ) unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) for the initial treatment of acute VTE was evaluated in a randomized open-label study which compared unfractionated heparin (initial dose 333",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    SQ followed by a fixed dose of 250",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    SQ every 12 hours) to LMW heparin (100 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    SQ of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    every 12 hours) in 708 adults with acute VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/46\">",
"     46",
"    </a>",
"    ]. As a departure from standard care, the aPTT was not monitored and platelet counts were not routinely obtained.",
"   </p>",
"   <p>",
"    The majority of patients were able to receive treatment on an outpatient basis. Further, despite concerns about lack of monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/47-49\">",
"     47-49",
"    </a>",
"    ], this trial indicated that the use of twice-daily unmonitored subcutaneous weight-adjusted UFH was as effective and safe as twice-daily subcutaneous LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and less expensive.",
"   </p>",
"   <p>",
"    A Cochrane review of 15 randomized controlled trials comparing subcutaneous UFH to continuous intravenous UFH or subcutaneous LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for the initial treatment of VTE found no statistically significant differences for any of the major efficacy and safety outcomes (ie, recurrent DVT, recurrent PE, major bleeding, death) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Prevention of VTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A different regimen, low dose subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , is often given for prophylaxis of venous thrombosis, primarily in the perioperative setting, but also in certain medical conditions. The usual dose is 5000 units subcutaneously two hours preoperatively and then every 8 or 12 hours postoperatively (ie, either three times daily or twice daily, respectively). Pooled data from meta-analyses have confirmed that low dose heparin reduces the incidence of all deep vein thrombosis, proximal deep vein thrombosis, and all pulmonary emboli, including fatal pulmonary emboli [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H18#H18\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Low dose unfractionated heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Low molecular weight (LMW)",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    appears to have equivalent or even superior efficacy to standard unfractionated heparin in this setting. (See",
"    <a class=\"local\" href=\"#H29\">",
"     'Use of LMW heparin'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link&amp;anchor=H20#H20\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Unfractionated versus LMW heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Available heparin nomograms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nomograms for the use of intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    other than the ones discussed above have also been published. They differ mainly in the initial rate of infusion, as well as the suggested changes to the infusion rate according to subsequent values of the aPTT. As an example, one of the dosing schedules for heparin cited in the 2012 ACCP Guidelines is an initial bolus of 5000 units followed by an infusion of 1333 units per hour (32,000",
"    <span class=\"nowrap\">",
"     units/24",
"    </span>",
"    hours), rather than the 1680 units per hour employed in the study noted above (",
"    <a class=\"graphic graphic_table graphicRef66081 \" href=\"mobipreview.htm?43/40/44683\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,15,41,44,53\">",
"     1,15,41,44,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A survey of available weight-based nomograms supports the view that they represent a safe and cost-effective strategy for unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    dosing in a number of different health care settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy are bleeding, thrombocytopenia, and osteoporosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there is a strong correlation between subtherapeutic aPTT values and recurrent thromboembolism, the relationship between supratherapeutic aPTT (aPTT ratio &gt;2.5) and bleeding is less clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/22\">",
"     22",
"    </a>",
"    ]. In a review of 416 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , hemorrhagic complications occurred in 5.5 percent and were more closely related to underlying clinical risk factors than an aPTT elevation above the therapeutic range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/55\">",
"     55",
"    </a>",
"    ]. Patients at particular risk are those who have had recent surgery or trauma, or who have other clinical factors which predispose to bleeding, such as peptic ulcer, occult malignancy, liver disease, hemostatic defects, age &gt;65 years, female gender, and a reduced admission hemoglobin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/22,44,55,56\">",
"     22,44,55,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of bleeding in a patient receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    depends upon the location and severity of bleeding, the risk of recurrent venous thromboembolism (VTE), and the level of the aPTT.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with recent VTE and clinically important",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      - associated bleeding should be considered for discontinuation of heparin and insertion of an inferior vena cava filter. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"       \"Placement of inferior vena cava filters and their complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      General measures that should be taken in any patient with anticoagulant-associated severe bleeding are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H32#H32\">",
"       \"Anticoagulants other than heparin and warfarin\", section on 'Emergency treatment of bleeding'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Heparin reversal with protamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;If urgent reversal of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    effect is required,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    can be administered by slow intravenous infusion (not greater than 20",
"    <span class=\"nowrap\">",
"     mg/minute",
"    </span>",
"    and no more than 50 mg over any 10 minute period). The appropriate dose of protamine sulfate is dependent upon the dose of heparin given and the elapsed time since the last heparin dose. Full neutralization of heparin effect is achieved with a dose of 1 mg protamine",
"    <span class=\"nowrap\">",
"     sulfate/100",
"    </span>",
"    units heparin. Because of the relatively short half life of intravenously administered heparin (approximately 30 to 60 min), the protamine sulfate dose used must be calculated by estimating the amount of heparin remaining in the plasma at the time that reversal is required.",
"   </p>",
"   <p>",
"    Bolus doses of more than 25 to 50 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    are seldom required. If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    had been given by subcutaneous injection, repeated small doses of protamine may be required because of prolonged heparin absorption from the various subcutaneous sites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Adverse reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have previously received protamine (including diabetic patients under treatment with protamine-containing insulin (eg, NPH, PZI) and those with fish allergy) have an approximately 1 percent risk of anaphylaxis when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    is administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) is a well-recognized and potentially fatal complication of heparin therapy, usually occurring within 5 to 10 days after the start of heparin therapy. The pathogenesis, clinical manifestations, diagnosis, and treatment of HIT are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Skin necrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin necrosis is a well-described complication of treatment with unfractionated or LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . Affected patients develop heparin-dependent antibodies but most do not experience thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H13#H13\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Skin necrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteoporosis has been reported in patients receiving unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for more than six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,57\">",
"     1,57",
"    </a>",
"    ]. Demineralization can result in the fracture of vertebral bodies or long bones, and the defect may not be entirely reversible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link&amp;anchor=H4#H4\">",
"     \"Drugs that affect bone metabolism\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Heparin contamination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious reactions following the use of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    were reported in late 2007, leading to urgent recall of some of these preparations. Adverse events included allergic or hypersensitivity-type reactions (eg, low blood pressure, shortness of breath, nausea, vomiting, diarrhea, abdominal pain), at least 81 reports of death, and an increase in the incidence of heparin-induced thrombocytopenia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/58-61\">",
"     58-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The suspect",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    products originated in China; heparin products available in at least 12 countries were contaminated with oversulfated chondroitin sulfate (OSCS), representing up to 30 percent by weight in suspect lots of heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. OSCS- containing heparin and synthetically derived OSCS induced hypotension associated with kallikrein activation and subsequent bradykinin generation when administered by intravenous infusion in swine, suggesting that this contaminant was responsible for the adverse reactions seen. Additionally, OSCS induced generation of C3a and C5a, potent anaphylaxis toxins derived from complement proteins.",
"   </p>",
"   <p>",
"    Whether this contamination was deliberate or the result of faulty processing of pig intestines, the major source for commercial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , is not clear. Currently available unfractionated heparin available in the United States is safe from this contamination now that the contaminant has been identified and assays have become available to screen for the presence of OSCS and other highly sulfated polysaccharide contaminants that can activate the contact system. These manufacturing and testing modifications have also resulted in a change in the reference standard for heparin, which has reduced the potency of unfractionated heparin products made in the United States by about 10 percent. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Effect of the change in heparin potency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , which undergoes an additional fragmentation process, has not been associated with these adverse reactions or contamination with chondroitin sulfate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     USE OF LMW HEPARIN",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Comparison with heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in current clinical use is polydispersed unmodified heparin, with molecular weight ranging from 3000 to 30,000 daltons and a mean molecular weight of approximately 15,000, corresponding to approximately 45 saccharide units. Low molecular weight (LMW) derivatives of commercial heparin have a molecular weight range from 2000 to 9000 daltons and a mean molecular weight of 4000 to 5000, corresponding to about 15 saccharide units [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,8,64-66\">",
"     1,8,64-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , LMW heparins inactivate factor Xa, but have a lesser effect on thrombin because most of the molecules do not contain enough saccharide units to form the ternary complex in which thrombin and AT are bound simultaneously (",
"    <a class=\"graphic graphic_figure graphicRef64839 \" href=\"mobipreview.htm?35/16/36110\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/8,9,67\">",
"     8,9,67",
"    </a>",
"    ]. As a result, LMW heparins (and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    ) do not prolong the aPTT. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link\">",
"     \"Clinical use of coagulation tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LMW heparins are at least as effective as unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for the treatment and prevention of VTE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. They are also equally effective for preventing thromboembolism prior to the use of long-term oral anticoagulation after a mechanical heart valve replacement as well as for patients with a mechanical valve who have a contraindication to the use of oral anticoagulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link&amp;anchor=H17#H17\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Stent thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=see_link&amp;anchor=H20#H20\">",
"     \"Prevention of venous thromboembolic disease in medical patients\", section on 'Unfractionated versus LMW heparin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link&amp;anchor=H19#H19\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\", section on 'Low molecular weight heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Advantages",
"    </span>",
"    &nbsp;&mdash;&nbsp;The LMW heparins have a number of advantages over unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/64\">",
"     64",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=see_link\">",
"     \"Low molecular weight heparin for venous thromboembolic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      They have greater bioavailability than UFH when given by subcutaneous injection.",
"     </li>",
"     <li>",
"      The duration of the anticoagulant effect is greater because of reduced binding to macrophages and endothelial cells, permitting administration only once or twice daily.",
"     </li>",
"     <li>",
"      The anticoagulant response (anti-Xa activity) to LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is highly correlated with body weight, permitting administration of a fixed dose. However, the dose may have to be adjusted for patients who are extremely obese or have renal failure (see",
"      <a class=\"local\" href=\"#H35\">",
"       'Special patient groups'",
"      </a>",
"      below)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Laboratory monitoring is not necessary in nonpregnant patients; in fact, there is little correlation between anti-Xa activity and either bleeding or recurrent thrombosis.",
"     </li>",
"     <li>",
"      They are much less likely to induce immune-mediated thrombocytopenia than unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      : 0 versus 2.7 percent in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/72\">",
"       72",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H2#H2\">",
"       \"Heparin-induced thrombocytopenia\", section on 'Incidence and risk factors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      They do not increase osteoclast number and activity as much as unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      , and may therefore produce less bone loss [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=see_link&amp;anchor=H5#H5\">",
"       \"Drugs that affect bone metabolism\", section on 'Low molecular weight heparin'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      can be safely administered in the outpatient setting [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two Cochrane reviews have explored the benefits of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    over unfractionated heparin, with the following conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with acute VTE, fixed-dose subcutaneous LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is more effective than adjusted-dose unfractionated heparin for reducing the incidence of symptomatic recurrent VTE, major hemorrhage, and all-cause mortality [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/77\">",
"       77",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Home management using LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      is cost effective, and is likely to be preferred by patients and become the norm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/78\">",
"       78",
"      </a>",
"      ], although reimbursement issues may exist among some third-party payers. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of lower extremity deep vein thrombosis\", section on 'Outpatient use'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Differences among products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Commercially available LMW heparins are made by many different processes (eg, nitrous acid, alkaline, or enzymatic depolymerization) and differ from one another both chemically and pharmacokinetically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/64,66\">",
"     64,66",
"    </a>",
"    ]. Variations in molecular weights of the various LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparations also result in different ratios of antifactor Xa to antifactor IIa activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"     1",
"    </a>",
"    ], although the clinical significance of these differences is unclear.",
"   </p>",
"   <p>",
"    There have been very few studies comparing different LMW heparins with respect to clinical outcomes. As a result, the doses of the different LMW heparins have been established empirically and are not necessarily interchangeable. Accordingly, the effectiveness and safety of each LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for each clinical setting (eg, renal insufficiency, VTE, unstable angina) must be tested separately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/66,79,80\">",
"     66,79,80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several different LMW heparins and one heparinoid are available for the prevention and treatment of venous thromboembolism in various countries. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link&amp;anchor=H6#H6\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Danaparoid'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three LMW heparins have been approved for clinical use in the United States (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"       tinzaparin",
"      </a>",
"      ). A closely related synthetic pentasaccharide,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , has also been approved, although this product is not generally classified as a low molecular weight",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link\">",
"       \"Therapeutic use of fondaparinux\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Additional LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      products are either commercially available in Europe and other countries or are in phase III clinical trials [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/66\">",
"       66",
"      </a>",
"      ]. These include fraxiparin, reviparin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"       nadroparin",
"      </a>",
"      , bemiparin, and certoparin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/81\">",
"       81",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One randomized study compared the clinical efficacy and safety of two different LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparations,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    (175 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    SQ every 24 hours) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    (200 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    SQ every 24 hours) given for at least five days as initial outpatient treatment in 505 patients with deep vein thrombosis or pulmonary embolus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There were no significant differences between the two treatment arms for the two composite end points, major hemorrhage and recurrent VTE, with 11 events in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    treatment arm (4.4 percent; 2 major hemorrhages and 9 recurrent VTE events) and 15 in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    treatment arm (5.9 percent; 5 major hemorrhages and 10 VTE recurrences).",
"   </p>",
"   <p>",
"    This study was terminated early when an interim analysis indicated that over 32,000 subjects would have to be enrolled in order to detect a statistically significant difference between the two treatment arms. It was therefore concluded that either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    provided effective and safe outpatient treatment for DVT or PE, and that the choice of agent might be based on practical issues (eg, price, drug delivery systems, availability) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Bleeding and protamine reversal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike its efficacy with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , protamine does not completely abolish the anti-Xa activity of LMW heparins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/83\">",
"     83",
"    </a>",
"    ]. However, for patients who experience bleeding while receiving LMW heparin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    anti-Xa units of LMW heparin) may reduce clinical bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,84\">",
"     1,84",
"    </a>",
"    ], presumably by neutralizing the higher molecular weight fractions of heparin within the product, which are thought to be most responsible for this complication. Smaller doses are needed if the LMW heparin was injected more than eight hours before the event requiring neutralization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Skin lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a prospective study of 320 consecutive patients receiving subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMW heparin in more than 90 percent), 24 (7.5 percent) developed skin lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/85\">",
"     85",
"    </a>",
"    ]. Delayed-type hypersensitivity (DTH) reactions were identified as the cause in all 24. Lesions were mostly either eczematous or pruritic erythematous placques; necrosis was not seen. Thrombocytopenia was noted in only one of the 24 patients. Significant risk factors for the development of such non-necrotic lesions were a body mass index &gt;25, female sex, and a treatment duration &gt;9 days. A subsequent report of 87 consecutive patients with heparin-induced (85 due to LMW heparin) skin lesions from the same investigators indicated that all lesions were caused by delayed-type IV-hypersensitivity reactions, rather than microvascular thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Switching to another LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    product in such cases is reasonable, although cross-reactivity between LMW heparin preparations has been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/87\">",
"     87",
"    </a>",
"    ]. In one report, all of the four patients who had developed DTH reactions to a LMW heparin were able to take the related product",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    without a cutaneous reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    reH",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Special patient groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain patient groups may require special dosing of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (eg, older age, obesity, renal failure, liver disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Anti-factor Xa testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;If there is any question as to the correct dose of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for these special groups, it is reasonable to consider anti-factor Xa activity testing. Dose reduction should be considered if the anti-factor Xa activity four hours after subcutaneous injection is excessive. However, \"optimal\" target ranges differ, depending not only upon the schedule of treatment (eg, once or twice daily), but also on the preparation used.",
"   </p>",
"   <p>",
"    Target (peak) ranges, measured four hours after dosing, are approximately 0.6 to 1.0 International",
"    <span class=\"nowrap\">",
"     Units/mL",
"    </span>",
"    for twice-daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/41/27286?source=see_link\">",
"     nadroparin",
"    </a>",
"    ; target levels for these two agents given once-daily are &gt;1.0 and 1.3 International",
"    <span class=\"nowrap\">",
"     Units/mL,",
"    </span>",
"    respectively, and are 0.85 and 1.05 for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h3\">",
"     Elderly patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, elderly patients should be treated with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    at the same weight-adjusted doses as employed in other adults. However, in elderly patients weighing &lt;45 kg, such dosing may result in an increased incidence of bleeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h3\">",
"     Obese patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are sparse on whether patients with extreme obesity should be given weight-based or fixed doses of the LMW heparins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/89-92\">",
"     89-92",
"    </a>",
"    ]. Available studies suggest no change in weight-based dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"     tinzaparin",
"    </a>",
"    for subjects with weights less than or equal to 144, 190, or 165 kg, respectively. The 2008 and 2012 ACCP Guidelines suggest that weight-based prophylactic dosing is preferable to fixed dosing for obese patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1,53\">",
"     1,53",
"    </a>",
"    ]. The table outlines information available on this subject for a number of the different LMW heparins and indications (",
"    <a class=\"graphic graphic_table graphicRef65464 \" href=\"mobipreview.htm?8/6/8302\">",
"     table 5",
"    </a>",
"    ). This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=see_link&amp;anchor=H14#H14\">",
"     \"Postoperative management of the critically ill obese patient\", section on 'Anticoagulants'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Renal failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no clear recommendation for the dosing of LMW heparins in patients with reduced renal function. However, it is important that such patients be adequately anticoagulated despite a potential increase in the rate of bleeding. This was shown in a study of 10,526 patients with VTE, most of whom were initially treated with LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/93\">",
"     93",
"    </a>",
"    ]. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The incidence of fatal pulmonary embolism within 15 days of diagnosis was 1.0, 2.6, and 6.6 percent for those with estimated creatinine clearances of &gt;60, 30 to 60, and &lt;30",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively.",
"     </li>",
"     <li>",
"      The rate of fatal bleeding from anticoagulation was highest for those with the lowest values of creatinine clearance (0.2, 0.3, and 1.2 percent for estimated creatinine clearances of &gt;60, 30 to 60, and &lt;30",
"      <span class=\"nowrap\">",
"       mL/min,",
"      </span>",
"      respectively).",
"     </li>",
"     <li>",
"      The rate of fatal PE was higher than the rate of fatal bleeding for all three groups of patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is unclear whether the increased risks of bleeding and fatal pulmonary embolism are directly related to renal insufficiency or the associated co-morbidities. Both are likely contributors.",
"   </p>",
"   <p>",
"    Setting a lower limit (eg, creatinine clearance &lt;30",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    on permissible renal function for weight-based dosing does not seem to be appropriate for some of the available products [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/79\">",
"     79",
"    </a>",
"    ]. This is because the pharmacokinetic response to impaired renal function may differ among LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/79,94\">",
"     79,94",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/44/21191?source=see_link\">",
"       Tinzaparin",
"      </a>",
"      sodium (Innohep), a LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      with a higher-than-average molecular weight distribution, did not exhibit accumulation in patients with creatinine clearances as low as 20",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/95,96\">",
"       95,96",
"      </a>",
"      ]. However, based upon preliminary data from the IRIS study (Innohep in Renal Insufficiency Study), including an increased risk for death, the United States FDA has advised that clinicians should consider the use of alternative treatments to Innohep when treating elderly patients &gt;70 years of age with renal insufficiency and VTE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was a significantly increased level of anti-factor Xa activity following the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours) in patients with a creatinine clearance &le;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/98\">",
"       98",
"      </a>",
"      ]. If enoxaparin is chosen in such a patient, using 50 percent of the recommended dose seems reasonable (eg, 30 mg",
"      <span class=\"nowrap\">",
"       once/day)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There was a significant bioaccumulation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      at a median of 6 days following the use of",
"      <strong>",
"       therapeutic",
"      </strong>",
"      doses of dalteparin (100",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      every 12 hours) in patients with a creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/99\">",
"       99",
"      </a>",
"      ]. If dalteparin is chosen in such a patient, frequent monitoring should be performed via determination of anti-factor Xa activity. No single dosing scheme could be suggested in this study, due to wide inter-individual variation.",
"     </li>",
"     <li>",
"      An increased risk of bleeding in patients with renal insufficiency (creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      was not reported with",
"      <strong>",
"       prophylactic",
"      </strong>",
"      doses (3000 anti-Xa",
"      <span class=\"nowrap\">",
"       units/daily)",
"      </span>",
"      of the LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      certoparin [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/100\">",
"       100",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A meta-analysis in non-dialysis-dependent patients with a creatinine clearance &le;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    also noted elevated levels of anti-Xa and an increased risk for major bleeding in those treated with weight- adjusted therapeutic doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/101\">",
"     101",
"    </a>",
"    ]. It was concluded that empirical dose adjustment of enoxaparin may reduce the risk for bleeding in such patients. The authors could make no conclusions regarding other LMW heparins in this setting.",
"   </p>",
"   <p>",
"    If a LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is to be used in a patient with renal failure, it has been recommended that frequent monitoring be performed via the direct determination of anti-factor Xa activity, since drug accumulation may occur over time in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, such monitoring may not be necessary in patients with impaired renal function receiving the LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    in prophylactic doses.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of 156 critically ill patients with severe renal insufficiency and a mean creatinine clearance of 19",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      (range: &lt;10 or on dialysis to 30",
"      <span class=\"nowrap\">",
"       mL/min),",
"      </span>",
"      the use of prophylactic doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      (5000 international units once daily) was not associated with an excessive anticoagulant effect due to drug accumulation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/102\">",
"       102",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective cohort study of patients with normal renal function or mild or severe renal insufficiency, patients received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"       dalteparin",
"      </a>",
"      in prophylactic doses (ie, fixed daily subcutaneous dose of 5000 Units with reduction to 2500 Units for a body weight &lt;50 kg and 7500 Units for a body weight &gt;100 kg) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/8/33930/abstract/103\">",
"       103",
"      </a>",
"      ]. In all three patient groups, adjusted peak anti-Xa levels were not different on day 10 compared with day one. No bioaccumulation &gt;30 percent could be found up to day 10 even in patients with severe renal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Mode of action",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is an indirect thrombin inhibitor which complexes with antithrombin, converting this circulating cofactor from a slow to a rapid inactivator of thrombin, factor Xa, and to a lesser extent, factors XIIa, XIa, and IXa. Low molecular weight (LMW) heparins have less antithrombin activity than does unfractionated heparin (UFH). (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Mechanism of action'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Monitoring of heparin activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticoagulant response to UFH is most frequently monitored through the activated partial thromboplastin time (aPTT). The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    titration assay and antifactor Xa assays can also be employed. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Heparin monitoring'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical use of coagulation tests\", section on 'Activated partial thromboplastin time'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LMW heparins are less efficient inhibitors of thrombin; their use cannot be monitored through use of the aPTT. If monitoring is required, LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    blood levels can be evaluated though antifactor Xa assays.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Monitoring of platelet counts",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all patients receiving unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) and some patients receiving LMW heparin, platelet counts must be obtained regularly to monitor for the development of heparin-induced thrombocytopenia. The frequency and timing of such counts depends on the clinical situation. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Platelet count monitoring'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H8#H8\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Onset and degree of thrombocytopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Dosing of the heparins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dosing of UFH or LMW heparins for treatment or prevention of VTE is discussed in the appropriate UpToDate treatment reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Reversing heparin",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unfractionated",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &mdash; If urgent reversal of the effect of unfractionated heparin is required,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"       protamine sulfate",
"      </a>",
"      can be administered by slow intravenous infusion. The appropriate dose of protamine sulfate is dependent upon the dose of heparin given and the elapsed time since the last heparin dose. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Heparin reversal with protamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      LMW",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      &mdash; Unlike its efficacy with unfractionated heparin, protamine does not completely abolish the anti-Xa activity of LMW heparins. However, for patients who experience bleeding while receiving LMW heparin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/9/11413?source=see_link\">",
"       protamine sulfate",
"      </a>",
"      may reduce clinical bleeding. (See",
"      <a class=\"local\" href=\"#H33\">",
"       'Bleeding and protamine reversal'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Use of LMW heparin in special patient groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain patient groups may require special dosing of LMW",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (eg, older age, obesity, renal failure). If there is any question as to the correct dose of LMW heparin for these special groups, it is reasonable to consider anti-factor Xa activity testing. (See",
"    <a class=\"local\" href=\"#H35\">",
"     'Special patient groups'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/1\">",
"      Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/2\">",
"      Baglin T, Barrowcliffe TW, Cohen A, et al. Guidelines on the use and monitoring of heparin. Br J Haematol 2006; 133:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/3\">",
"      Hirsh J, Anand SS, Halperin JL, et al. Guide to anticoagulant therapy: Heparin : a statement for healthcare professionals from the American Heart Association. Circulation 2001; 103:2994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/4\">",
"      Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/5\">",
"      Choay J, Petitou M, Lormeau JC, et al. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/6\">",
"      Marcum JA, McKenney JB, Rosenberg RD. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparinlike molecules bound to the endothelium. J Clin Invest 1984; 74:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/7\">",
"      Danielsson A, Raub E, Lindahl U, Bj&ouml;rk I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J Biol Chem 1986; 261:15467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/8\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/9\">",
"      Jordan RE, Oosta GM, Gardner WT, Rosenberg RD. The kinetics of hemostatic enzyme-antithrombin interactions in the presence of low molecular weight heparin. J Biol Chem 1980; 255:10081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/10\">",
"      Turpie AG. Pharmacology of the low-molecular-weight heparins. Am Heart J 1998; 135:S329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/11\">",
"      Cheng S, Morrow DA, Sloan S, et al. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Circulation 2009; 119:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/12\">",
"      Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/13\">",
"      Colvin BT, Barrowcliffe TW. The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: second revision. BCSH Haemostasis and Thrombosis Task Force. J Clin Pathol 1993; 46:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/14\">",
"      Hirsh J, van Aken WG, Gallus AS, et al. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation 1976; 53:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/15\">",
"      Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:454S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/16\">",
"      Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/17\">",
"      Gehrie E, Laposata M. Test of the month: The chromogenic antifactor Xa assay. Am J Hematol 2012; 87:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/18\">",
"      Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/19\">",
"      Raschke R, Hirsh J, Guidry JR. Suboptimal monitoring and dosing of unfractionated heparin in comparative studies with low-molecular-weight heparin. Ann Intern Med 2003; 138:720.",
"     </a>",
"    </li>",
"    <li>",
"     Available on the United States Pharmacopeia website at: file://www.usp.org/hottopics/heparin.html (Accessed on October 08, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/21\">",
"      Kearon C, Johnston M, Moffat K, et al. Effect of warfarin on activated partial thromboplastin time in patients receiving heparin. Arch Intern Med 1998; 158:1140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/22\">",
"      Hull RD, Raskob GE, Rosenbloom D, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990; 322:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/23\">",
"      Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:340S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/24\">",
"      Linkins LA, Dans AL, Moores LK, et al. Treatment and prevention of heparin-induced thrombocytopenia: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e495S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/25\">",
"      Uprichard J, Manning RA, Laffan MA. Monitoring heparin anticoagulation in the acute phase response. Br J Haematol 2010; 149:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/26\">",
"      Levine MN, Hirsh J, Gent M, et al. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/27\">",
"      Ranucci M, Isgr&ograve; G, Cazzaniga A, et al. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. Perfusion 1999; 14:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/28\">",
"      Ranucci M, Isgr&ograve; G, Cazzaniga A, et al. Different patterns of heparin resistance: therapeutic implications. Perfusion 2002; 17:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/29\">",
"      Langley PG, Keays R, Hughes RD, et al. Antithrombin III supplementation reduces heparin requirement and platelet loss during hemodialysis of patients with fulminant hepatic failure. Hepatology 1991; 14:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/30\">",
"      Lemmer JH Jr, Despotis GJ. Antithrombin III concentrate to treat heparin resistance in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2002; 123:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/31\">",
"      Schwartz RS, Bauer KA, Rosenberg RD, et al. Clinical experience with antithrombin III concentrate in treatment of congenital and acquired deficiency of antithrombin. The Antithrombin III Study Group. Am J Med 1989; 87:53S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/32\">",
"      Menache D, O'Malley JP, Schorr JB, et al. Evaluation of the safety, recovery, half-life, and clinical efficacy of antithrombin III (human) in patients with hereditary antithrombin III deficiency. Cooperative Study Group. Blood 1990; 75:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/33\">",
"      Bucur SZ, Levy JH, Despotis GJ, et al. Uses of antithrombin III concentrate in congenital and acquired deficiency states. Transfusion 1998; 38:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/34\">",
"      Mannucci PM, Boyer C, Wolf M, et al. Treatment of congenital antithrombin III deficiency with concentrates. Br J Haematol 1982; 50:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/35\">",
"      Winter JH, Fenech A, Bennett B, Douglas AS. Transfusion studies in patients with familial antithrombin III (ATIII) deficiency: half-disappearance time of infused ATIII and influence of such infusion on platelet life-span. Br J Haematol 1981; 49:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/36\">",
"      Brandt P. Observations during the treatment of antithrombin-III deficient women with heparin and antithrombin concentrate during pregnancy, parturition, and abortion. Thromb Res 1981; 22:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/37\">",
"      Schulman S, Tengborn L. Treatment of venous thromboembolism in patients with congenital deficiency of antithrombin III. Thromb Haemost 1992; 68:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/38\">",
"      Lechner K, Kyrle PA. Antithrombin III concentrates--are they clinically useful? Thromb Haemost 1995; 73:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/39\">",
"      Fennerty AG, Thomas P, Backhouse G, et al. Audit of control of heparin treatment. Br Med J (Clin Res Ed) 1985; 290:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/40\">",
"      Wheeler AP, Jaquiss RD, Newman JH. Physician practices in the treatment of pulmonary embolism and deep venous thrombosis. Arch Intern Med 1988; 148:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/41\">",
"      Cruickshank MK, Levine MN, Hirsh J, et al. A standard heparin nomogram for the management of heparin therapy. Arch Intern Med 1991; 151:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/42\">",
"      Hylek EM, Regan S, Henault LE, et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med 2003; 163:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/43\">",
"      Hurewitz AN, Khan SU, Groth ML, et al. Dosing of unfractionated heparin in obese patients with venous thromboembolism. J Gen Intern Med 2011; 26:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/44\">",
"      Hull RD, Raskob GE, Rosenbloom D, et al. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/45\">",
"      Raschke RA, Reilly BM, Guidry JR, et al. The weight-based heparin dosing nomogram compared with a \"standard care\" nomogram. A randomized controlled trial. Ann Intern Med 1993; 119:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/46\">",
"      Kearon C, Ginsberg JS, Julian JA, et al. Comparison of fixed-dose weight-adjusted unfractionated heparin and low-molecular-weight heparin for acute treatment of venous thromboembolism. JAMA 2006; 296:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/47\">",
"      Carson JL. Subcutaneous unfractionated heparin vs low-molecular-weight heparin for acute thromboembolic disease: issues of efficacy and cost. JAMA 2006; 296:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/48\">",
"      Goldhaber SZ, Berkwits M. Trials that matter: can patients with venous thromboembolism be treated with fixed-dose subcutaneous unfractionated heparin? Ann Intern Med 2006; 145:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/49\">",
"      DeLoughery TG. Update in hematology. Ann Intern Med 2007; 147:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/50\">",
"      Vardi M, Zittan E, Bitterman H. Subcutaneous unfractionated heparin for the initial treatment of venous thromboembolism. Cochrane Database Syst Rev 2009; :CD006771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/51\">",
"      Clagett GP, Reisch JS. Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis. Ann Surg 1988; 208:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/52\">",
"      Collins R, Scrimgeour A, Yusuf S, Peto R. Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. N Engl J Med 1988; 318:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/53\">",
"      Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e24S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/54\">",
"      Bernardi E, Piccioli A, Oliboni G, et al. Nomograms for the administration of unfractionated heparin in the initial treatment of acute thromboembolism--an overview. Thromb Haemost 2000; 84:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/55\">",
"      Juergens CP, Semsarian C, Keech AC, et al. Hemorrhagic complications of intravenous heparin use. Am J Cardiol 1997; 80:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/56\">",
"      Campbell NR, Hull RD, Brant R, et al. Aging and heparin-related bleeding. Arch Intern Med 1996; 156:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/57\">",
"      Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration: Information on heparin sodium injection. Available on the FDA website at: www.fda.gov/cder/drug/infopage/heparin/default.htm (Accessed on May 28, 2008).",
"    </li>",
"    <li>",
"     United States Food and Drug Administration. Medwatch. Available at: www.fda.gov/medwatch/safety/2008/heparin_recall.htm (Accessed on May 28, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/60\">",
"      Greinacher A, Warkentin TE. Contaminated heparin. N Engl J Med 2008; 359:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/61\">",
"      Blossom DB, Kallen AJ, Patel PR, et al. Outbreak of adverse reactions associated with contaminated heparin. N Engl J Med 2008; 359:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/62\">",
"      Kishimoto TK, Viswanathan K, Ganguly T, et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008; 358:2457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/63\">",
"      Guerrini M, Beccati D, Shriver Z, et al. Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol 2008; 26:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/64\">",
"      Hirsh J, Levine MN. Low molecular weight heparin. Blood 1992; 79:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/65\">",
"      Prandoni P. Heparins and venous thromboembolism: current practice and future directions. Thromb Haemost 2001; 86:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/66\">",
"      White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol 2003; 121:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/67\">",
"      De Caterina R, Husted S, Wallentin L, et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007; 28:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/68\">",
"      Nurmohamed MT, Rosendaal FR, B&uuml;ller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992; 340:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/69\">",
"      Dolovich LR, Ginsberg JS, Douketis JD, et al. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/70\">",
"      Montalescot G, Polle V, Collet JP, et al. Low molecular weight heparin after mechanical heart valve replacement. Circulation 2000; 101:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/71\">",
"      Batchelor WB, Mahaffey KW, Berger PB, et al. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. J Am Coll Cardiol 2001; 38:1608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/72\">",
"      Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995; 332:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/73\">",
"      Bhandari M, Hirsh J, Weitz JI, et al. The effects of standard and low molecular weight heparin on bone nodule formation in vitro. Thromb Haemost 1998; 80:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/74\">",
"      Monreal M, Lafoz E, Olive A, et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994; 71:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/75\">",
"      Koopman MM, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996; 334:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/76\">",
"      Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996; 334:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/77\">",
"      van Dongen CJ, van den Belt AG, Prins MH, Lensing AW. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database Syst Rev 2004; :CD001100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/78\">",
"      Schraibman IG, Milne AA, Royle EM. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2001; :CD003076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/79\">",
"      Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162:2605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/80\">",
"      Thorevska N, Amoateng-Adjepong Y, Sabahi R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/81\">",
"      Riess H, Koppenhagen K, Tolle A, et al. Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis. Thromb Haemost 2003; 90:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/82\">",
"      Wells PS, Anderson DR, Rodger MA, et al. A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism. Arch Intern Med 2005; 165:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/83\">",
"      Harenberg J, Gnasso A, de Vries JX, et al. Inhibition of low molecular weight heparin by protamine chloride in vivo. Thromb Res 1985; 38:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/84\">",
"      Massonnet-Castel S, Pelissier E, Bara L, et al. Partial reversal of low molecular weight heparin (PK 10169) anti-Xa activity by protamine sulfate: in vitro and in vivo study during cardiac surgery with extracorporeal circulation. Haemostasis 1986; 16:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/85\">",
"      Schindewolf M, Schwaner S, Wolter M, et al. Incidence and causes of heparin-induced skin lesions. CMAJ 2009; 181:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/86\">",
"      Schindewolf M, Kroll H, Ackermann H, et al. Heparin-induced non-necrotizing skin lesions: rarely associated with heparin-induced thrombocytopenia. J Thromb Haemost 2010; 8:1486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/87\">",
"      Bank I, Libourel EJ, Middeldorp S, et al. High rate of skin complications due to low-molecular-weight heparins in pregnant women. J Thromb Haemost 2003; 1:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/88\">",
"      Schindewolf M, Scheuermann J, Kroll H, et al. Low allergenic potential with fondaparinux: results of a prospective investigation. Mayo Clin Proc 2010; 85:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/89\">",
"      Al-Yaseen E, Wells PS, Anderson J, et al. The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. J Thromb Haemost 2005; 3:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/90\">",
"      Hainer JW, Barrett JS, Assaid CA, et al. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study. Thromb Haemost 2002; 87:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/91\">",
"      Patel JP, Roberts LN, Arya R. Anticoagulating obese patients in the modern era. Br J Haematol 2011; 155:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/92\">",
"      Freeman A, Horner T, Pendleton RC, Rondina MT. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity. Am J Hematol 2012; 87:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/93\">",
"      Monreal M, Falg&aacute; C, Valle R, et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med 2006; 119:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/94\">",
"      Mah&eacute; I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007; 97:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/95\">",
"      Siguret V, Pautas E, F&eacute;vrier M, et al. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost 2000; 84:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/96\">",
"      Siguret V, Gouin-Thibault I, Pautas E, Leizorovicz A. No accumulation of the peak anti-factor Xa activity of tinzaparin in elderly patients with moderate-to-severe renal impairment: the IRIS substudy. J Thromb Haemost 2011; 9:1966.",
"     </a>",
"    </li>",
"    <li>",
"     Available on the United States FDA website at: www.fda.gov/medwatch/safety/2008/safety08.htm#Innohep (Accessed on December 03, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/98\">",
"      Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/99\">",
"      Schmid P, Brodmann D, Odermatt Y, et al. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost 2009; 7:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/100\">",
"      Bauersachs R, Schellong SM, Haas S, et al. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost 2011; 105:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/101\">",
"      Lim W, Dentali F, Eikelboom JW, Crowther MA. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med 2006; 144:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/102\">",
"      Douketis J, Cook D, Meade M, et al. Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. Arch Intern Med 2008; 168:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/8/33930/abstract/103\">",
"      Schmid P, Brodmann D, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function. J Thromb Haemost 2009; 7:552.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1348 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-C008A65255-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33930=[""].join("\n");
var outline_f33_8_33930=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H40\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      USE OF HEPARIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PRACTICAL ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Limitations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Heparin induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Heparin monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Effect of the change in heparin potency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Addition of warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Prolonged baseline aPTT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Platelet count monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Heparin resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Antithrombin deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Interference with thrombophilia testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ADMINISTRATION AND EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Treatment of VTE",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Intravenous heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Subcutaneous UFH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Prevention of VTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Available heparin nomograms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Heparin reversal with protamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Adverse reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Skin necrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Heparin contamination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      USE OF LMW HEPARIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Comparison with heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Advantages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Differences among products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Bleeding and protamine reversal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Skin lesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Special patient groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Anti-factor Xa testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      - Elderly patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      - Obese patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Mode of action",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Monitoring of heparin activity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Monitoring of platelet counts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Dosing of the heparins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Reversing heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Use of LMW heparin in special patient groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1348\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1348|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/16/36110\" title=\"figure 1\">",
"      Mechanisms of action of heparin LMW heparin and fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1348|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/22/44396\" title=\"table 1\">",
"      Thrombophilia test interference",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/40/44683\" title=\"table 2\">",
"      Heparin protocol I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/6/21612\" title=\"table 3\">",
"      Heparin protocol II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/28/42444\" title=\"table 4\">",
"      Weight based heparin nomogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/6/8302\" title=\"table 5\">",
"      LMWH doses in obese patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/46/18153?source=related_link\">",
"      Anticoagulation during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/36/24136?source=related_link\">",
"      Antithrombin (ATIII) deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31688?source=related_link\">",
"      Antithrombotic treatment of acute ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/36/4682?source=related_link\">",
"      Clinical use of coagulation tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11930?source=related_link\">",
"      Evaluation of the patient with established venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/59/43961?source=related_link\">",
"      Low molecular weight heparin for venous thromboembolic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/12/23752?source=related_link\">",
"      Management of inherited thrombophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/2/32810?source=related_link\">",
"      Postoperative management of the critically ill obese patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/21/36186?source=related_link\">",
"      Prevention of venous thromboembolic disease in medical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_8_33931="PAIN RULES mnemonic for palliative care";
var content_f33_8_33931=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F74629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F74629&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    PAIN RULES mnemonic for assessing symptomatology in palliative care*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         P",
"        </strong>",
"        ain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         A",
"        </strong>",
"        norexia and other appetite or oral intake related issues",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         I",
"        </strong>",
"        ncontinence and other genitourinary symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         N",
"        </strong>",
"        ausea and other gastrointestinal symptoms (constipation, vomiting, diarrhea)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist_other\">",
"        <span class=\"small\">",
"         &nbsp;",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         R",
"        </strong>",
"        espiratory symptoms (dyspnea, cough)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         U",
"        </strong>",
"        lcerations and other skin complaints",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         L",
"        </strong>",
"        evel of functioning (expressed, for instance, as ECOG or Karnofsky, or other performance scales)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         E",
"        </strong>",
"        nergy and other related issues such as fatigue or asthenia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         S",
"        </strong>",
"        edation, sleep and other side effects of treatment (including opioids and chemotherapy)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECOG: Eastern Cooperative Oncology Group.",
"     <br>",
"      * Prevalence of symptoms derived from J Pain Symptom Manage 2006; 31:58.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33931=[""].join("\n");
var outline_f33_8_33931=null;
var title_f33_8_33932="Indications for PT and aPTT testing";
var content_f33_8_33932=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F88913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F88913&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for obtaining PT testing alone, aPTT testing alone, or PT and aPTT testing combined",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical circumstance(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        PT",
"        <br/>",
"        testing alone",
"       </td>",
"       <td class=\"subtitle1\">",
"        aPTT",
"        <br/>",
"        testing alone",
"       </td>",
"       <td class=\"subtitle1\">",
"        PT and aPTT",
"        <br/>",
"        testing combined",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Monitoring anticoagulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Warfarin only (without heparin)",
"       </td>",
"       <td class=\"centered\">",
"        &radic;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Therapeutic unfractionated heparin (without warfarin)",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &radic;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Transitions between heparin and warfarin therapy",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Patient assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assessment of patients with signs or symptoms of hemorrhage or thrombosis",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &radic;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assessment of patients with history of condition known to be associated with risk of bleeding or thrombosis due to",
"        <strong>",
"         extrinsic",
"        </strong>",
"        coagulation pathway abnormalities, either genetic or acquired",
"       </td>",
"       <td class=\"centered\">",
"        &radic;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assessment of patients with history of condition known to be associated with risk of bleeding or thrombosis due to",
"        <strong>",
"         intrinsic",
"        </strong>",
"        coagulation pathway abnormalities, either genetic or acquired",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &radic;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Assessment of risk of hemorrhage or thrombosis in patients who are going to have a medical intervention known to be associated with increased risk of bleeding or thrombosis",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &ndash;",
"       </td>",
"       <td class=\"centered\">",
"        &radic;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PT: prothrombin time; aPTT: activated partial thromboplastin time.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33932=[""].join("\n");
var outline_f33_8_33932=null;
var title_f33_8_33933="PARMA trial survival";
var content_f33_8_33933=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F65432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F65432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 497px\">",
"   <div class=\"ttl\">",
"    Overall survival of patients in the PARMA trial of transplantation in relapsed aggressive non-Hodgkin lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 477px; height: 294px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier plots of overall survival of patients with relapsed aggressive non-Hodgkin lymphoma in the PARMA trial randomized to receive either 6 cycles of DHAP chemotherapy plus radiotherapy (blue curve) or 2 cycles of DHAP followed by radiotherapy, intensive chemotherapy, and autologous bone marrow transplantation (red curve).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Philip, T, et al. N Engl J Med 1995; 333:1540.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33933=[""].join("\n");
var outline_f33_8_33933=null;
var title_f33_8_33934="Lateral xray transverse fracture little toe";
var content_f33_8_33934=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Nondisplaced transverse fracture of little toe: lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note how difficult it is to identify the phalanx on the lateral view, let alone recognize that it is fractured and minimally displaced (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33934=[""].join("\n");
var outline_f33_8_33934=null;
var title_f33_8_33935="PTH and calcium";
var content_f33_8_33935=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 561px\">",
"   <div class=\"ttl\">",
"    Serum parathyroid hormone (PTH) concentrations in hypercalcemia and hypocalcemia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 541px; height: 557px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Serum PTH concentrations according to the serum total calcium concentration in various disease states. The normal range is shown in the white box. The sigmoidal curve (green) is derived from a calcium citrate infusion protocol administered to 38 normal subjects. Serum PTH and calcium values are low in hypoparathyroidism (open blue boxes) and high in primary hyperparathyroidism (blue squares). The serum calcium concentration is high and serum PTH is appropriately low in patients with non-PTH-induced hypercalcemia of malignancy (red circles).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Haden ST, Brown EM, Hurwitz S, et al. The effects of age and gender on parathyroid hormone dynamics. Clin Endocrinol 2000; 52:329.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_8_33935=[""].join("\n");
var outline_f33_8_33935=null;
